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PREFACE 
Cystic Fibrosis (CF) is an autosomic recessive disorder that 
affecting mostly Caucasians at an incidence of 1 in every 2500- 
4000 live births and a carrier frequency of 1:25-30, depending on 
the geographical region. It is estimated that in Europe there are 
about 30,000 CF patients and about the same number in North 
America. This life-threatening disease is caused by the dysfunction 
of the CF transmembrane conductance regulator (CFTR) protein, 
whose gene was cloned in 1989 after several years of intense work 
by three laboratories. The CFTR protein functions as a cAMP-
activated and phosphorylation-regulated chloride (Cl-) ion channel 
at the apical membrane of epithelial cells. CFTR is essential for the 
normal ionic transport of the epithelia lining the airways, the 
intestinal tract (including pancreatic and bile ducts), the sweat 
glands and the male reproductive tract. CF is dominated by 
progressive lung dysfunction (which is the main cause of morbidity 
and mortality) due to major infections particularly by Pseudomonas 
aeruginosa, but other symptoms include pancreatic insufficiency, 
elevated sweat electrolytes and male infertility. 
There were big expectations in the cloning of the gene, as it 
was believed that delivery of a correct copy of CFTR to cure the 
patients by a gene therapy approach would soon follow. Several 
hurdles, not the least a lack of basic biology knowledge, precluded 
this and currently gene therapy came to a halt, except for the UK. 
Symptomatic therapies such as powerful antibiotics and robust 
chest therapy to remove the thick mucus on a daily basis have 
nevertheless pushed every year the mean life expectancy from the 
first decade in the 1970’s to the 4th decade. 
Undoubtedly that 20 years of intensive research in the CF 
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field have led to many advances, but there are still many open 
questions and the slow progress into getting the correct answers 
has prevented a fast path to a cure, which aims to correct the basic 
defect underlying CF. A number of these open questions concern 
the CFTR protein itself. 
CFTR is a multidomain protein and member of the ATP-
binding cassette (ABC) transporters superfamily (ABCC7) and is 
composed of two membrane-spanning domains (MSDs), two 
nucleotide-binding domains (NBDs) and a large regulatory domain 
(RD) where multiple phosphorylations occur. Since the CFTR gene 
was identified, more than 1,600 gene variants have been reported. 
However, the deletion of a trinucleotide resulting in the loss of 
phenylalanine at polypeptidic position 508 (F508del) in NBD1 
accounts approximately for 70% of the CF chromosomes 
worldwide and is present in ~90% of CF patients in, at least one 
allele. 
The major impact of the F508del mutation is to cause CFTR 
protein to misfold and thus be intracellularly retained, namely in the 
endoplasmic reticulum (ER). Indeed, the ER quality control (ERQC) 
recognizes incorrect folding of F508del-CFTR and sends it to early 
degradation, thus preventing it from trafficking to the cellular 
membrane. Many efforts have thus been dedicated to understand 
and overcome both the folding defect of F508del-CFTR and the 
ERQC mechanisms responsible for its intracellular retention. 
Although chemical, pharmacological and genetic factors have been 
described to rescue F508del-CFTR to the cell membrane, only 
recently small molecules restoring its folding and trafficking defects 
have started to hit the clinical setting, by entering Phase II clinical 
trials. Nevertheless, major efforts are in place to understand the 
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mechanism by which these small molecules affect F508del-CFTR.  
To better understand how the ERQC recognizes F508del-
CFTR and thus fully elucidate the molecular basis of this major CF-
causing mutation, it is nevertheless important to understand the 
exact nature of CFTR structure and it’s (mis)folding. Ultimately, a 
good characterization of the structural differences between wild-
type (wt) and F508del-CFTR may allow drug-designed therapy. 
The high-resolution structure of full-length CFTR (in the 1-digit 
range) is still unknown due to the difficulty in obtaining this 
membrane protein at elevated purity in high yield so as to 
crystallize. Nevertheless, in recent years several high-resolution 
structures of the first NBD1 of CFTR (where F508del locates) of 
both murine and human origin (and more recently of NBD2) have 
become available. Comparison of such crystal structures of wt- and 
F508del-NBD1 indicates that the mutation does not affect the gross 
morphology of NBD1, but causes a change in the surface 
properties near to the NBD1 mutation. Differences between these 
structures also suggest that both wt and mutant NBD1 have two 
mobile regions. The first mobile region actually corresponds to the 
first 25 residues of the RD and was termed the regulatory 
extension (RE). The second mobile region is a 30-residue insertion, 
which, intriguingly, is absent in NBDs from other ABC transporters, 
called the regulatory insertion (RI). Moreover, protein modelling 
studies of full-length CFTR based on the high-resolution of other 
ABC transporters, together with low-resolution 2D structural studies 
of CFTR by cryo-EM have shed some light into full-length CFTR 
structure. Notwithstanding, experimental data, namely mutagenesis 
coupled to biochemical approaches, is critically needed to validate 
such models, namely in their details. 
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The doctoral work described in this thesis focuses exactly 
on dissecting particular aspects of in vivo folding of full-length 
CFTR by biochemical approaches, so as to validate existing 
structural models obtained by computational methods. Firstly, a 
cross-species comparative approach was used to investigate 
whether CFTR domains are structurally interchangeable between 
human (h) and murine (m) CFTR, by generating and analyzing a 
large set of hmCFTR chimeric proteins. Secondly, a similar 
biochemical approach was used to evaluate the impact of the two 
above-mentioned regions of NBD1 the regulatory insertion (RI) and 
regulatory extension (RE) on the in vivo processing of wt- and 
F508del-CFTR. 
In Chapter I of this thesis, a detailed overview of the CF 
field is provided, starting by focusing briefly on the history and 
clinical aspects of CF and also on the discovery of the CF gene. 
Then, the state-of-the-art from research on biogenesis, processing 
and degradation of the CFTR protein is summarized. Finally, the 
molecular basis of the F508del mutation defect and recent 
experimental data and models on CFTR tertiary structure are 
presented. 
Chapter II presents an overall description of the 
experimental procedures (materials and methods) used throughout 
this doctoral work. 
Chapter III includes data describing the use of human-
murine CFTR chimeras to identify critical residues in the 
polypeptidic chain different between human and murine CFTR, 
causing protein misprocessing. Moreover, by using existing 
molecular models, a second-site mutation (L581F) was identified 
as being potentially capable of reverting the defect of one 
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processing mutant (K584E), which was then experimentally 
demonstrated to act indeed as a revertant. 
Chapter IV describes the structural/functional impact of 
removing the regulatory extension (ΔRE) at the C terminal of NBD1 
and the regulatory insertion (ΔRI) located within the domain. 
Additionally, the effects of mutations which previously 
described/suggested to correct the folding defect of F508del-CFTR 
(R1070W and G550E) were evaluated on the processing of the 
ΔRE and ΔRI CFTR variants. 
In Chapter V, a general integrative discussion of the results 
is provided, putting them in perspective with state-of-the-art 
structural data in the CFTR field. Perspectives for future work are 
also highlighted in this chapter.   
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SUMMARY  
Impairment of the Cystic Fibrosis (CF) transmembrane 
conductance regulator (CFTR) gene causes CF, a fatal genetic 
disease.  
In the first part of this doctoral work, we used hm-chimeras 
generated by homologous recombination where the major 
structural domains of mCFTR were inserted on an hCFTR 
backbone. We indirectly evaluated the in vivo folding of such 
hmCFTR chimeras by assessing their maturation after transfecting 
cells with various chimeric constructs of hmNBD1, hmNBD2 and 
hmR domain (RD). Results show that similarly to wt-CFTR, most 
chimeric proteins are processed to the cell membrane, except for 
two chimeras: one containing part of the first nucleotide binding 
domain (NBD1) from mCFTR and another containing part of 
mNBD2. Six key amino acid (aa) variations in between human and 
mNBD1 and twelve in NBD2 were selected for in vitro mutagenesis 
and assessed for their maturation properties. Biochemical and 
functional analyses of these mutants stably expressed revealed 
that they were all processed except for K584E. As in a model of 
hCFTR Lys584 interacts with Leu581, we replaced this residue in 
hCFTR-K584E by the correspondent murine aa (L581F) and found 
that such replacement rescues K584E-CFTR trafficking. We 
conclude that hmCFTR chimeras are a valuable tool to elucidate 
interactions between different domains of CFTR. Our data also 
demonstrate that human-murine CFTR chimeras may be used to 
validate structural models of full length CFTR. 
On the second part of the present work, we studied the 
structural/functional impact of removing a regulatory extension (RE) 
at the C terminal of NBD1 and a regulatory insertion (RI) located 
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within the domain by producing ΔRE and ΔRI variants of WT- and 
F508del-CFTR. Moreover, we propose to evaluate the effect of 
mutations which have already been described/suggested to correct 
the folding defect of F508del-CFTR such as R1070W and G550E 
on the CFTR variants lacking the RE and RI. Results show that 
∆RE, ∆RI and ∆RE/∆RI are efficiently processed on wt-, but not on 
F508del-CFTR, although ∆RE/∆RI-wt-CFTR exhibits lower steady-
state maturation levels. Functional characterization by iodide efflux 
shows that ΔRE- and ΔRI-wt respond to agonists, ΔRE causing a 
significant functional decrease, despite that ΔRE-wt is 
predominantly at the plasma membrane and ΔRI-wt mostly in the 
ER with faint membrane staining. Neither ΔRE- nor ΔRI-F508del 
exhibit detectable activity, being both located in the ER. Finally, 
R1070W-ΔRI-F508del (but not R1070W-ΔRE-F508del) undergoes 
maturation. Altogether, these results help to elucidate the structural 
changes that account for the F508del defect and may be of use to 
elucidate the mechanism of action of correctors. 
 
Keywords: Cystic Fibrosis; CFTR; human and murine chimeras; 
NBD1 mutants, revertant mutations; regulatory extension; 
regulatory insertion. 
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RESUMO 
 A Fibrose Quística (FQ) é a doença genética fatal de 
carácter autossómico recessivo mais comum na população 
Caucasiana, apresentando uma incidência de 1 em cada 2500-
4000 recém-nascidos. A FQ é dominada pela doença pulmonar 
crónica no seguimento de infecções bacterianas, sendo esta a 
principal causa de morbilidade e mortalidade. Outros sintomas 
típicos da FQ incluem insuficiência do pâncreas exócrino, aumento 
da concentração de sódio e cloreto no suor e infertilidade 
masculina. No pulmão dos doentes com FQ, o desequilíbrio iónico 
do líquido que reveste as vias respiratórias (ASL, do inglês airway 
surface liquid) leva à acumulação de um muco espesso resultando 
num ineficiente transporte mucociliar, o qual facilita a colonização 
por bactérias, principalmente Pseudomonas aeruginosa. Esta 
infecção bacteriana e o processo inflamatório que daí resulta, 
geram um ciclo vicioso que conduz à perda progressiva da função 
pulmonar e morte precoce do doente. Até a identificação da causa 
molecular da doença, a medição da concentração salina no suor 
(elevada na FQ) era praticamente a única ferramenta de 
diagnóstico, continuando hoje em dia a ser o principal método para 
diagnosticar a FQ. 
A FQ é causada por mutações no gene CFTR (do inglês 
cystic fibrosis transmembrane conductance regulator) que codifica 
para uma proteína com o mesmo nome que tem como principal 
função transportar iões cloreto (Cl-) na membrana apical das 
células epiteliais. A proteína CFTR, composta por uma única 
cadeia polipeptídica com 1480 resíduos de aminoácidos, pertence 
à vasta família de proteínas dependentes de ATP (do inglês 
adenosin triphosphate), designadas por transportadores ABC (do 
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inglês ATP-binding cassette). A estrutura terciária da CFTR inclui 
dois domínios transmembranares (MSD 1 e 2, do inglês membrane 
spanning domain) que formam o poro do canal, dois domínios 
citosólicos de ligação a nucleótidos (NBD 1 e 2, do inglês 
nucleotide binding domain), que dimerizam para ligar e hidrolisar 
ATP, e um domínio regulador central (RD, do inglês regulatory 
domain), ausente nos outros trasportadores ABC e que contém 
múltiplos locais de fosforilação responsáveis ela regulação da sua 
actividade da CFTR como canal iónico. A CFTR passa ao estado 
activo mediante fosforilação do RD, pela proteína cinase A (PKA) 
dependente do cAMP (do inglês cyclic adenosine monophosphate) 
seguida de ciclos de abertura e fecho do canal assegurados por 
ligação e hidrólise de ATP, alternadamente em cada um dos dois 
NBDs. 
 A biogénese da proteína CFTR inicia-se com a sua síntese 
e folding no retículo endoplasmático (ER, do inglês endoplasmic 
reticulum), onde é glicosilada co-traducionalmente originando a 
forma imatura da proteína, também conhecida por banda B. O 
controlo de qualidade do ER (ERQC, do inglês endoplasmic 
reticulum quality control) tem aqui um papel preponderante no 
reconhecimento de conformações aberrantes da proteína, as quais 
são rapidamente enviadas para a via de degradação proteolítica 
do retículo (ERAD, do inglês endoplasmic reticulum associated 
degradation) associada à ubiquitina e ao proteassoma. Vários 
chaperones moleculares e seus co-chaperones participam neste 
processo. Depois de adquirir a sua conformação correcta, a forma 
imatura da CFTR sai do RE para o aparelho de Golgi onde sofre 
novas alterações pós-traducionais, nomeadamente glicosilações 
complexas, originando assim a respectiva forma matura totalmente 
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glicosilada, vulgarmente designada por banda C. Por mecanismos 
ainda não totalmente esclarecidos, a proteína atinge o seu local de 
acção, a membrana apical da célula, de onde é internalizada para 
vesículas na região sub-apical. Através duma regulação fina, os 
processos de exo- e endocitose são então responsáveis pelo 
controlo do número de moléculas CFTR na membrana. 
 Até a data, foram identificadas mais de 1,600 variantes no 
gene CFTR. Contudo, uma única mutação, a delecção de três 
resíduos de nucleótidos, resultando na delecção do resíduo de 
fenilalanina da posição 508 (F508del) da cadeia polipeptídica da 
CFTR, no NBD1, é a mutação mais comum causadora de FQ. De 
facto, a F508del surge mundialmente em cerca de 70% dos 
cromossomas FQ e está presente em ~90% dos doentes pelo 
menos em um dos alelos. Quando em homozigotia, está associada 
a um fenótipo clínico grave. A segunda e terceira mutações mais 
frequentes no mundo, ocorrendo com frequência ligeiramente 
superior a 1%, são G542X e G551D. Apesar da extensa 
informação descritiva que existe sobre as alterações génicas 
causadoras de FQ, não estão ainda completamente elucidados os 
mecanismos moleculares da fisiopatologia desta doença, em 
particular quando associada às múltiplas variantes do gene CFTR. 
Assim, não será de estranhar que, dada a elevada incidência da 
mutação F508del, a maioria dos esforços de investigação e no 
desenvolvimento de novas estratégias terapêuticas destinadas a 
corrigir o defeito básico da FQ, tenham focado esta mutação. 
Desta forma, pretende-se compreender o defeito primário e início 
da cascata de eventos patológicos que geram a doença FQ, e 
também, dessa forma, conceber estratégias para a sua correcção. 
 O principal impacto da mutação F508del ocorre ao nível do 
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folding do NBD1, onde se localiza o que também tem impacto 
global da proteína, impedindo a correcta interacção dos seus 
domínios e originando conformações aberrantes. Tal defeito de 
folding, leva à retenção no ER das conformações aberrantes, que 
são subsequentemente enviadas para degradação no 
proteassoma que, desta forma, nunca chega a atingir o seu 
correcto local de acção na membrana celular. Dada a localização 
da mutação no NBD1 seria plausível pensar que este defeito de 
tráfego da F508del-CFTR resultaria da reduzida eficiência de 
folding do domínio NBD1 mutante. Porém, o domínio F508del-
NBD1 isolado in vitro tem praticamente a mesma estabilidade 
termodinâmica que o domínio wt-NBD1. No entanto, dados 
recentes, nomeadamente do nosso laboratório, indicam que o 
defeito de folding da F508del-CFTR já deverá já estar associado, 
pelo menos em parte ao F508del-NBD1. Em primeiroo lugar 
mutações que ajudam a solubilizar o F508del-NBD1 in vitro 
também causam a recuperação do processamento e tráfego 
membranar da proteína CFTR completa in vivo. Em segundo lugar, 
a afinidade do F508del-NBD1 com o chaperone molecular Hsp70 
(que reconhece resíduos hidrófobos expostos à superfícieda 
cadeias polipeptídicas) avaliada in vitro por SPR (surface plasmon 
resonance) é 5 vezes superior à interacção do mesmo chaperone, 
demonstrando que o NBD1 mutante se apresenta numa 
conformação menos nativa do que o wt-NBD1. 
Para além de exibir um processamento deficiente, a 
proteína completa (full-lenght) mutante, F508del-CFTR, é também 
mais instável in vivo do que a wt-CFTR na membrana. Quando 
manipulada de modo a ser promovida a sua inserção na 
membrana celular (p. ex, por incubação das células a baixa 
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temperatura, 26 ºC), o funcionamento (gating) da F508del-CFTR 
como canal de cloreto apresenta uma deficiente regulação, o que 
sugere que mantém ainda uma conformação alterada. 
Efectivamente, encontra-se bem descrito que o defeito de folding 
da proteína F508del-CFTR é sensível à temperatura, ou seja, 
incubações a baixa temperatura (26 ºC) levam à correção parcial 
dos defeitos de maturação e de tráfego. Como o mutante retém 
ainda alguma actividade, embora reduzida, a procura de agentes 
farmacológicos que promovam o folding da F508del-CFTR e/ou a 
sua saída do ER é presentemente objecto de grandes esforços 
quer por parte da indústria farmacêutica quer do meio académico. 
Vários estudos têm contribuído para a identificação de alguns 
agentes que, à semelhança da baixa temperatura, são capazes de 
restabelecer, pelo menos parcialmente, o tráfego e processamento 
da proteína F508del-CFTR. Foram até à data descritos alguns 
agentes químicos, farmacológicos e mais recentemente, também 
genéticos, com capacidade de reverter este defeito primário. 
 O conhecimento da estrutura detalhada 3D de uma 
proteína é muito importante não apenas para compreender o seu 
folding, função, especificidade e consequências funcionais das 
mutações causadoras de doença ao nível molecular, mas é 
também um pré-requisito para o desenho racional de fármacos. Só 
assim será possível identificar os melhores locais onde 
plausivelmente se ligarão potenciais compostos terapêuticos e 
também contribuir para o conhecimento dos mecanismos 
patofisiológicos desta doença. 
Várias estruturas de alta-resolução do NBD1 da CFTR 
foram publicadas, incluindo a estrutura cristalina do F508del-
NBD1, a qual apresenta apenas diferenças subtis, 
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comparativamente a estrutura do wt-NBD1. A comparação entre as 
estruturas dos dois domínios (wt- e F508del-NBD1) também 
sugere diferenças em duas regiões de levada mobilidade. A 
primeira destas regiões corresponde aos primeiros 25 resíduos do 
RD foi designada por extensão regulatória (RE, do inglês, 
Regulatory Extension). A segunda região de elevada mobilidade 
consiste numa inserção de 30 resíduos, a qual está curiosamente 
ausente nos NBDs dos outros transportadores ABC, chamando-se 
assim inserção regulatória (RI, do inglês, Regulatory Insertion). 
Adicionalmente, estudos de modelação proteíca da proteína CFTR 
completa, baseados nas estruturas de alta-resolução de outros 
transportadores ABC, em conjunto com estudos estruturais 2D de 
baixa-resolução da CFTR por crio-EM começaram a elucidar a 
estrutura da CFTR completa. No entanto, é extremamente 
necessário consubstanciar tais modelos com resultados 
experimentais, nomeadamente por abordagens de mutagénese 
acoplada a bioquímica, a fim de se poder validar tais modelos a 
nível detalhado. 
 O primeiro objectivo deste trabalho doutoral foi identificar 
resíduos críticos na cadeia polipeptídica da CFTR que poderão 
eventualmente reverter o misfolding da proteína mutante e assim 
aprofundar a compreensão da estrutura terciária da CFTR. Para 
isso, foram utilizadas quimeras da proteína CFTR com origem 
humana e murina. A análise bioquímica destas quimeras permitiu 
identificar uma mutação presente no domínio NBD1 (K584E) que 
origina uma proteína CFTR misfolded a qual apresenta um tráfego 
deficiente nas células BHK (do inglês baby hamster kidney) não 
atingindo a membrana celular e não desempenhando as suas 
funções como canal de cloreto. Ao inserir-se esta mutação num 
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modelo computacional do NBD1-NBD2 da CFTR humana, foi 
identificado um resíduo (L581F) na sua vizinhança, cuja interacção 
poderia permitir o restabelecimento do tráfego e processamento 
deste mutante. Por análise bioquímica e funcional verificámos 
efcetivamente que o duplo mutante (L581F/K584E) apresenta uma 
eficiência de processamento e função como canal de cloreto 
semelhantes a proteína wt-CFTR. Estes resultados comprovam 
assim que a L581F reverte o defeito observado na K584E. Em 
suma, estes resultados mostram como a utilização de quimeras 
CFTR humanas-murinas contribuem para a identificação de 
resíduos críticos, responsáveis por diferenças tanto a nível 
funcional como conformacional entre a CFTR humana e murina, 
podendo desta forma ajudar a validar os modelos estruturais para 
a proteína CFTR completa. 
O segundo objectivo deste trabalho foi estudar da 
importância das regiões RE, localizada em C-terminal do NBD1, e 
RI em N-terminal deste domínio, no processamento e tráfego in 
vivo da proteína CFTR completa. Através da análise comparativa 
das sequências polipeptídicas da CFTR humana e verificou-se que 
estas região estão ausentes no NBD1 dos outros transportadores 
ABC.  Neste estudo, verificámos que a remoção quer da região RE 
quer da região RI da proteína wt-CFTR humana não tem um efeito 
significativo nos níveis do seu processamento ou função. 
Adicionalmente, também mostrámos que a remoção destas 
regiões da F508del-CFTR não leva ao restabelecimento do 
processamento ou tráfego deste mutante. Foram também 
produzidas novas linhas celulares que para além da ausência 
destas regiões da CFTR, incluem mutações anteriormente 
descritas como revertentes da F508del-CFTR, nomeadamente a 
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G550E e a R1070W. Os resultados mostram que a variante 
R1070W-ΔRI-F508del (mas não a R1070W-ΔRE-F508del) é 
processada e atinge a membrana celular. 
 
Globalmente, os estudos desenvolvidos neste trabalho 
doutoral demonstraram a importância da abordagens in vivo, não 
só bioquímica, como também de biologia celular e estudos 
funcionais para a validação dos modelos estruturais da proteína 
CFTR. A utilização destes mutantes em futuros estudos com 
pequenas moléculas será ainda importante para a identificação de 
motivos estruturais, potencialmente envolvidos na ligação dessas 
moléculas. Poderão ainda ajudar a sugerir novos locais de ligação 
de outras estruturas químicas direccionadas para a correcção do 
defeito básico da proteína CFTR mutante. 
 
 
 
 
Palavras-Chave: Fibrose Quística ; CFTR; quimeras humanas e 
murinas; mutantes NBD1; mutações revertentes.   
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cDNA  mRNA complementary DNA 
CF  Cystic fibrosis  
CFTR  CF transmembrane conductance regulator 
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I - GENERAL INTRODUCTION 
1. CYSTIC FIBROSIS OVERVIEW 
1.1 BRIEF HISTORY	  
Cystic fibrosis (CF), also known as mucoviscidosis, is a 
genetic disorder with autosomal recesive inheritance.  CF is ranked 
as one of the most widespread life-shortening genetic diseases 
amoung Caucasians affecting about 1 in 2500-4000  live births and 
a carrier frequency of 1 in 25 individuals (Collins, 1992).   
CF has been in the human population for centuries, as 
shown in many early reports dating back to the middle of the 17th 
Century of infants that almost certainly had CF. 
However, CF has a unique desease has only been 
recognized in the late 1930s. Dr. Dorothy Andersen, made the first 
clear description of CF in 1938 and also named it as "cystic fibrosis 
of the pancreas” (Andersen, 1938).   
In the early 1940s, the term “mucoviscidosis” was 
introduced by Dr Sydney Faber, broadening the spectrum of the 
disease beyond the pancreas (Farber, 1943).  In 1946, patient’s 
studies deduced that cystic fibrosis was a recessive condition, 
probably due to mutation of a single gene (Anderson and Hodges, 
1946). 
 During the 1950s, a heat wave in the east coast of the 
United States, lead to the identification of an increased salt content 
in the sweat of cystic fibrosis patients (Di Sant'Agnese et al., 1953).  
This major clinical achievement by Paul Di Sant’Agnese, allowed 
from there onward an accurate diagnosis.  The sweat test, still his 
the most common diagnostic tool for CF.  
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 In the first half of the 1980s, it became evident that in every 
organ impaired by CF there was a malfunction of the epithelial 
tissue.  In fact, it was shown that epithelia of cystic fibrosis patients 
are relatively impermeable to chloride.  These findings were 
followed by a major effort to find the gene responsible for CF. 
Finally in 1989, the gene was cloned and the protein named as a 
cystic fibrosis transmembrane conductance regulator (CFTR) 
(Kerem et al., 1989; Riordan et al., 1989; Rommens et al., 1989).  
 
1.2 CLINICAL DESCRIPTION  
CF is a pleiotropic disease mainly characterized by elevated 
sweat chloride (Cl-) and sodium (Na+) concentrations, exocrine 
pancreatic insufficiency, intestinal obstruction called meconium 
ileus and male infertility (Welsh et al., 1995; Zielenski and Tsui, 
1995). Other manifestations include cirrhosis of the liver and 
diabetes mellitus (Welsh et al., 1995).  The major cause of 
morbidity and mortality is however a chronic respiratory disease, 
characterized by colonization of the conducting airway manly by 
Pseudomonas aeruginosa.  Once bacterial infections set in, the 
mucociliary clearance becomes inefficient and recurrent infections 
originate an exacerbate inflammatory response contributing to 
respiratory failure and ultimately to death.   
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2. CYSTIC FIBROSIS GENE TO CFTR PROTEIN  
The CFTR gene or ABCC7 is located on the long (q) arm of 
chromosome 7, band 31 (7q31-7q32), spanning a genetic region of 
190kb.  It contains 27 exons that after splicing result in a 6.5 kb 
mRNA that directs the synthesis of a protein with 1480 aa residues 
(Riordan et al., 1989) (Figure I.1).   
 
Figure I.1 – Scheme representing the CFTR gene, mRNA and protein.  N – 
N-terminus; MSD – membrane-spanning domain; NBD – nucleotide-binding 
domain; R – regulatory domain; C – C-terminus (see section 3 for more 
details).  Adapted from (Zielenski and Tsui, 1995). 
 
More then 1600 CF-causing mutations have already been 
listed on the CFTR Mutation Database 
(http://www.genet.sickkids.on.ca/cftr/).  However, one single 
mutation a 3 bp deletion in exon 10 named F508del accounts for 
almost two-thirds of all CF cases worldwide (Kerem et al., 1989).   
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2.1 CFTR BIOGENESIS, PROCESSING, DEGRADATION  
CFTR is an integral membrane glycoprotein functioning as 
a cAMP-activated and phosphorylation-regulated chloride (Cl-) ion 
channel at the apical membrane of epithelial cells.  As a membrane 
protein, CFTR must follow the general route for the export of 
proteins from the endoplasmic reticulum (ER) to the cell membrane 
through the Golgi termed the secretory pathway.  Like other 
proteins entering the secretory pathway, CFTR assembly begins 
with synthesis and folding in the endoplasmic reticulum (ER).   
CFTR biogenesis begins in cytosolic ribosomes that are 
targeted through the signal recognition particle (SRP) to the ER 
membrane translocon (Sec61 complex) via the SRP receptor (Lu et 
al., 1998; Skach, 2000).  The CFTR polypeptidic chain emerging 
from the ribosome is thus co-translationally inserted into the ER 
through the sequential and coordinated action of signal and stop 
transfer signals (Skach, 2000).  The stop transfer sequences 
terminate ongoing translocation and direct hydrophobic 
transmembrane helices out of the translocon and into the lipid 
bilayer.  Although both CFTR halves have a similar transmembrane 
topology, Lu et al. (Lu et al., 1998) described a distinct mechanism 
by which they become inserted into the membrane.  Indeed, the N-
terminal segments can be inserted either co- or post-translationally 
in which one of the transmembrane (TM) segments functions as 
the starting signal for translocation (Lu et al., 1998; Skach, 2000).   
After insertion into the ER membrane, the newly 
synthesized wild-type (wt) – and F508del – CFTR is N-glycosylated 
through the addition of two core-oligosaccharides, a 14-unit 
oligosaccharidic branched structure (GlcNAc2-Man9-Glc3), on two 
asparagines residues located in the fourth extracellular loop (N894 
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and N900) giving rise to the core-glycosylated form known as band 
B with a molecular mass of about 150 kDa.  Once checked for its 
correct folding, the core-glycosylated form of wt-CFTR migrates to 
the Golgi complex where it undergoes further glycosylation and 
produces the mature form referred to as 170-180 kDa band C 
(Amaral, 2004).  In contrast, because F508del-CFTR is not 
correctly folded, this mutant protein is almost completely retained at 
the ER (Cheng et al., 1990) from where it is degraded via the 
ubiquitin-proteasome pathway  (Jensen et al., 1995; Ward et al., 
1995). These results suggest that the F508del mutation disrupts 
the conformation and folding of the CFTR protein, thus preventing 
its maturation and export from the ER by quality control (QC) 
mechanisms that prelude the deployment of improperly folded 
membrane secretory proteins into the Golgi complex (Vashist and 
Ng, 2004) 
The inequity between folded and misfolded conformation is 
performed by the ERQC where molecular chaperones play a major 
role.  Chaperones typically recognize and bind to hydrophobic 
amino acid residues exposed at the other surface of unfolded 
polypeptides thereby preventing unproductive aggregation and 
promoting proper folding or send unfolded polypeptides for 
degradation.  By contributing to the ERQC chaperones play a vital 
role in the survival of the cell (Barral et al., 2004; Hohfeld et al., 
2001).  Additionally altered protease activity provided in vivo 
evidence that in the ER, two distinct immature and mature forms of 
CFTR exist and have different conformations being F508del-CFTR 
unable to achieve the latter (Zhang et al., 1998).  Molecular 
chaperones acting on both sides of the ER membrane may play a 
role in modulating the conversion between these two CFTR 
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conformations.   
Farinha and colleagues (Farinha and Amaral, 2005) have 
proposed a model in which the ERQC of CFTR occurs via a two-
step mechanism (Figure I.2).  Briefly, once biogenesis and insertion 
in the ER membrane occur, CFTR nascent domains associate with 
cytosolic chaperones Hsc70/Hdj2 or Hsp70/Hdj-1. The 
Hsc70/Hsp70 association forms the first ER quality control 
checkpoint.  If Hsc70 remains associated for too long to its 
substrate it recruits CHIP (C-terminus of Hsc70 interacting protein) 
and causes the mutant (F508del-CFTR) to be degraded through 
the Hsc70-CHIP-UbcH5a pathway.  CHIP has E3 ubiquitin (Ub)  
ligase activity that sends proteins to the Ub-proteasome pathway 
for degradation (Meacham et al., 2001).   This pathway was termed 
ER associated degradation (ERAD).  The E2 Ubc6 may also 
contribute to F508del-CFTR ERAD (Lenk et al., 2002).  The second 
ERQC checkpoint is the calnexin cycle.  Contrarily to what happens 
with F508del-CFTR, wt-CFTR proceeds in the folding pathway 
acquiring its native conformation through successive rounds of 
release-deglucosylation and reglucosylation-rebinding to calnexin 
(Farinha and Amaral, 2005).   However, in case of prolonged 
residency in the calnexin cycle, misfolded proteins become a 
substrate of ER mannosidase I.  This enzyme removes the terminal 
mannose from the middle branch, which is the predicted signal for 
translocon delivery and GERAD (glycan-moiety dependent ERAD).  
According to this model, F508del-CFTR follows a major 
degradative pathway from the first (Hsc70-dependent) ERQC 
checkpoint, whereas misfolded wt CFTR undergoes proteolytic 
GERAD at the second (calnexin-dependent) (Farinha and Amaral, 
2005).   
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Figure I.2 – Model for the major degradation pathway of wt- and F508del-
CFTR, glycan-mediated-ERAD (GERAD).  F508del-CFTR is degradated in an 
earlier ER checkpoint involving Hsc70/Hsp70 whereas misfolded wt-CFTR 
undergoes degradation at a latter calnexin-dependent checkpoint.  (1) 
Hsp70/Hdj-2 (Hsp70/Hdj-1) bind to nascent CFTR protein.  Prolonged 
retention of F508del-CFTR enables CHIP to interact with Hsc70/Hsp70 and 
leads to degradation.  (2) wt-CFTR proceeds through the folding pathway 
through the interaction with calnexin. (3) Through successive rounds of 
deglucosylation-release wt-CFTR acquires its native conformation.  (4) 
Reglucosylation and rebinding to calnexin.  (5) Once CFTR is successfully 
folded it exits the ER and proceeds to the secretory pathway. (6) Prolonged 
interaction with the calnexin cycle cause misfolded CFTR to become a 
substrate of mannoidase I.  (7) Target protein is sent to ERAD (Farinha and 
Amaral, 2005). 
 
 
The movement of nascent proteins from the site of 
synthesis to their final cellular or extracellular destinations involves 
transport through a distinct series of vesicular compartments.  
Being CFTR an integral membrane protein, it will traffic through all 
the compartments of the protein secretory pathway as it migrates to 
the plasma membrane.  There are two ways by which proteins can 
leave the ER: if the protein is misfolded, it is retrotranslocated and 
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degraded by ERAD and if the protein achieves a proper native fold, 
it is transported to the Golgi via COP II (coat protein II) coated 
vesicles (Lee et al., 2004).   
Different models have been proposed regarding the early 
stages of CFTR trafficking to the plasma membrane (Figure I.3).   
The first model (model 1, Figure I.3), is based on the low levels of 
wt-CFTR in the Golgi region that may reflect a limiting step in 
selective recruitment by the ER export machinery (Bannykh et al., 
2000; Gentzsch et al., 2003).  CFTR is then inefficiently selected 
for ER export to the Golgi via COP II vesicles. In this model, exiting 
the ER is dependent on masking ER retention signals on the CFTR 
protein to allow its incorporation into the COPII coated vesicles 
such as diacidic motifs o-arginine-framed tripeptide (AFTs) (Wang 
et al., 2004; Yoo et al., 2002).  The second model (model 2, Figure 
I.3) accounts for the complete absence of CFTR in central regions 
of the Golgi being the total pool of wt-CFTR (folded and misfolded) 
captured equally efficiently by the COPII machinery.  Conversely, 
only CFTR protein that has undergone a degree of maturation will 
reach the cis-Golgi, while the rest is recycled back to the ER in 
COPI vesicles (Bannykh et al., 2000).  Proteins recycled back from 
the ER re-enter the folding process and are either sent once more 
to the cis-Golgi, or converge towards ubiquitination and are 
degraded in the proteasome (Bonifacino and Rojas, 2006).  The 
third model (model 3, Figure I.3), proposes a non-conventional 
pathway of ER-derived vesicles via tubular structures migrating 
peripherally to the central Golgi elements directly to the trans-Golgi 
or endocytic compartments (Bannykh et al., 2000).  Although, it is 
worth mentioning that this non-conventional pathway is cell-type 
dependent and may reflect a property of the heterologous 
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overexpression system used (Yoo et al., 2002).   
 
 
Figure I.3 – Models for CFTR trafficking through the early secretory pathway.  
Each of the panels illustrates a possible pathway for movement of CFTR from 
the ER through the early secretory. Wild-type CFTR is shown by the green 
(folded, mature form) or red (misfolded form) (Bannykh et al., 2000).   
 
Finally, transport of CFTR protein from the trans-Golgi to 
the plasma membrane can occur indirectly via transcytosis from the 
basolateral membrane and from recycling endosomes or directly to 
the apical membrane by Golgi-derived vesicles (Kleizen et al., 
2000).  CFTR localization to the apical membrane is dependent on 
interactions with PDZ domains containing proteins (Short et al., 
1998; Wang et al., 1998).  The PDZ proteins have been shown to 
be expressed at the apical membrane of human epithelia where 
they play a structural and regulatory role for many membrane-
based processes (Bretscher et al., 2000).   
Despite the large amount of information already gathered 
on ERQC it is still not completely known how these mechanisms 
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distinguish a native conformation from a misfolded one. However, it 
is generally accepted that the folded state of proteins depends both 
on intrinsic structural motifs (determined by the protein’s primary 
sequence) and on extrinsic factors present in the cellular 
environment (molecular chaperones). Understanding factors that 
correct folding and/or prevent ER retention of F508del-CFTR may 
ultimately be of benefit for the treatment of CF (Amaral, 2005).  
 
2.2 CF CAUSING MUTATION.  CLASSES OF MUTATIONS	  
Many CFTR mutations have already been identified and all 
are known to affect the function of the protein in some way.  
However, it is difficult to ascertain which of the above individual 
steps of CFTR processing and function is responsible for different 
defects in protein production and function. This led Tsui (Tsui, 
1992) and subsequently Welsh and Smith (Welsh and Smith, 1993) 
to propose five mechanisms by which mutations disrupt CFTR Cl- 
channel function (Figure I.4).  This classification is important for the 
development of therapeutic strategies, as mutations in different 
classes will likely need to be tackled differently when aiming to 
correct the basic defect. 
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Figure I.4 – Classes of CFTR mutations.  (Normal) CFTR protein in the 
plamas membrane of cells functioning as a Cl- channel; (I) class I mutation: 
prevent translation; (II) class II: defective processing; (III) class III: defective 
regulation; (IV) class IV: defective conductance; (V) class V: reduced 
synthesis.  Adapted from  (Zielenski and Tsui, 1995).   
 
Class I mutations cause premature termination of CFTR 
mRNA translation in the nucleus, resulting in severely decreased of 
absent CFTR protein production. A number of class I mutants are 
due to nonsense, frameshift or aberrant splicing.  Class II 
mutations lead to degradation of the protein within the ER and little 
or no functional protein is transferred to the cell membrane. 
Mutants in this class include F508del.  The disease severity in this 
class correlates with the amount of correctly processed protein that 
is able to reach the apical membrane.  Class III mutants are 
located correctly at the cell membrane but are unable to function as 
a cAMP-activated Cl- channel.  Class IV mutants are also properly 
located but have altered conductance or gating properties causing 
a reduced Cl- efflux rate through the CFTR channel. Class V 
mutants cause a reduction in the levels of functional CFTR often 
due to alternative splicing or recycling.   
Interestingly, little correlation between mutation classes and 
severity of airway disease has been described. This indicates that 
the progression of CF lung disease may be significantly influenced 
by environmental factors or immunological events that are not 
Chapter I 
 14 
influenced directly by the specific CFTR genotype. In patients who 
are compound heterozygotes for CF, the "milder" mutation acts as 
dominant; this ressembles the no-disease condition of carriers of 
the CF gene. 
 
2.3 UNDERSTANDING THE MOLECULAR BASIS OF THE F508DEL 
MUTATION DEFECT  
In the case of CF, a single mutation, F508del (located in 
NBD1), is responsible for approximately 70% of the CF 
chromosomes worldwide.  Given such high incidence and the fact 
that only symptomatic treatments have been developed for CF, it is 
critical to understand the effect of this mutation in the life cycle of 
CFTR.  This mutation gives rise not only to a folding defect, 
evidenced by the failure of a full-length protein to mature and reach 
the plasma membrane, but also a retention in the ER and 
subsequent degradation by the proteasome (Cheng et al., 1990; 
Lukacs et al., 1994; Ward et al., 1995).   
The mutation is known to act at two levels: the first to 
decrease the folding yield and transitions between the intermediate 
states in the folding of NBD1 itself, and the second, to prevent 
interaction of the NBD1 surface with the rest of the protein 
(Serohijos et al., 2008).  In the folding mechanism two competing 
processes can occur: the progression from the unfolded to the 
folded/native state along the folding pathway or the formation of 
misfolded conformations (Chen et al., 2008). Qu and colleagues 
(Qu et al., 1997) have shown that F508del is a kinetic folding 
mutant that affects an early step in the folding process.  This 
corresponds to a significant energy barrier between the native state 
and the step affected by the mutation, thus precluding the use of 
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native state ligands (eg. chaperones) to promote proper folding.  
The deletion is likely to impose a kinetic division in the folding 
pathway leading to the appearance of misfolded conformations, 
subsequently giving rise to the recognition of a disruption in the 
folding of NBD1 and targeting the protein for degradation (Qu et al., 
1997; Thibodeau et al., 2005).   
Additionally, many studies have revealed that residue F508 
may contribute to the interactions between domains in CFTR.  
Chen and colleagues (Chen et al., 2004) have reported that the 
presence of the mutation interferes in the ability of NBD1 and 
transmembrane domain 1 (MSD1) to form a tight association.  This 
disrupts the packing of the TM segments between MSD1 and 
MSD2 which in turn prevents the protein to mature.  Also, studies 
on other ABC transporters (BtuCD from Escherichia coli and MsbA 
from Vibrio cholera) found that analogue residues of F508 lie at the 
interface between the NBDs and the MSDs and contribute to the 
interaction between these domains (Locher et al., 2002).  
Furthermore, the phenylalanine aromatic side chain was described 
to participate in an aromatic cluster with residues from the 
cytoplasmic loop 4 (CL4) (Serohijos et al., 2008).  Indeed, 
Serohijos and colleagues have established the precise 
intramolecular contact formed by the F508 side chain in the 
assembly of the N- and C-terminal portions of the protein.  Their 
findings may provide some insight into the role of this interface in 
the regulation of the CFTR channel.   
Another possibility is that QC of the cell may specifically 
recognize some primary structure motifs exposed in F508del-CFTR 
due to an altered conformation, being this a crucial step in 
regulating its maturation.  CFTR has four arginine-framed 
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tripeptides (AFTs) along its polypepetide chain, which act as a 
negative ER retention signal.  This means that in wt-CFTR these 
AFTs are hidden, thus allowing the protein to traffic to the Golgi.  
Most probably, these signals are exposed in the abnormal 
conformation of F508del-CFTR thus preventing the protein from 
processing through the Golgi (Chang et al., 1999) (see section 
2.5.3 – Genetic revertants).  Alternatively, or in addition, F508del-
CFTR may turn inaccessible short di-acidic ER motifs.  These have 
been proposed to be involved in the transport of some membrane 
proteins through the ER exiting sites, functioning as a positive ER 
export signal motifs (Lewis et al., 2004; Riordan, 1999). 
Although classified as a trafficking mutant F508del leads 
primarily to a protein folding defect with altered protein trafficking or 
kinesis secondary to altered folding (Qu et al., 1997).  Ultimately 
understanding what causes the defective folding and maturation of 
this mutant will contribute to a more effective design of novel 
therapeutics for CF patients.   
 
2.4 CFTR FUNCTION AS A CHLORIDE  CHANNEL 
Proteins belonging to the family of ABC transporters are 
responsible for active transport of substrates across cell 
membranes, where ATP hydrolysis serves as the source of energy 
to drive the transport.  CFTR is functionally distinct from other ABC 
transporters because it permits bidirectional permeation of anions 
rather than vectorial transport of solutes (Riordan, 2005). The early 
hypothesis regarding the function of CFTR protein revolved around 
three possibilities.  The first postulated that CFTR was an ATP-
driven transporter.  The second hypothesis held that CFTR 
functioned as a regulator of a separate channel molecule and 
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finally the third hypothesis proposed that CFTR was itself a 
regulated Cl- channel.  Ultimately, compelling proof that CFTR 
exhibited regulated Cl- channel activity came with the reconstitution 
of CFTR in a planar lipid bilayer (Bear et al., 1992).  
 
2.4.1 R-DOMAIN PHOSPHORYLATION 
In the model currently accepted for the mechanism of 
channel function and regulation, the opening and closing of the Cl- 
channel is tightly regulated by the cellular balance of kinase and 
phosphatase activity and by ATP levels. Activation of the cAMP-
dependent PKA (and PKC) causes the phosphorylation of serine 
residues within the R domain (Sheppard and Welsh, 1999).  It has 
been shown that intramolecular interaction between the R domain 
(RD) and either the N-terminal or NBD1 are required to regulate 
CFTR function (Baker et al., 2007).  This conformation change in 
the RD disrupts its interaction with NBD1 and allows ATP to bind to 
the NBDs, forming the NBD1-NBD2 dimer. The R domain is much 
more than a simple on-off switch of CFTR. In fact, once 
phosphorylated, the RD activates and stimulates the Cl- channel, 
probably by interaction with the NBDs to enhance their ATP affinity 
(Sheppard and Welsh, 1999).  The mechanism of channel gating is 
not fully understood but it is believed that the introduction of 
negative charges and the appropriate conformational changes are 
important (Baker et al., 2007; Ostedgaard et al., 2001).    
 
2.4.2 ATP BINDING AND HYDROLYSIS BY THE NBDS 
Once the R domain is phosphorylated, channel gating is 
regulated by a cycle of ATP hydrolysis at the NBDs. Protein 
phosphatases dephosphorylate the R domain and the channel 
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returns to its quiescent state (Sheppard and Welsh, 1999).  
Different models of how gating is driven by ATP hydrolysis have 
been proposed. Carson and colleagues suggested a model were 
ATP binding occurs simultaneously at both NBDs in the closed 
conformation; hydrolysis at NBD1 opens the channel, while 
hydrolysis at NBD2 closes the channel (Carson et al., 1995). In 
another model presented by Sheppard and Welsh (Sheppard and 
Welsh, 1999), the transition from closed to open state occurs when 
ATP binds at NBD2 and from open to closed depends on ATP 
binding at NBD1.  Although there are other models in the literature 
and many aspects remain to be clarified, the ATP-dependent 
gating cycle includes two crucial steps; first, phosphorylation of the 
R domain and secondly binding of ATP for NBD dimerization.  One 
model accounts for the dynamics observed in CFTR channel gating 
and proposes that dimer formation and channel opening is initiated 
by the stable binding of ATP at the NBD1: NBD2 dimer.  This in 
turn leads to conformational changes in the MSDs and 
consequently opening of the channel.  The conversion of ATP to 
ADP reduces the nucleotide binding affinity towards the NBD 
binding site, facilitating dissociation of ADP and thereby disrupting 
the NBD dimer interaction, leading to channel closing  (Figure I.5) 
(Gadsby et al., 2006).     
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Figure I.5 – Model of ATP-dependent gating cycle of phosphorylated CFTR 
channels.  The R domain is omitted.  ATP (yellow) remains tightly bound to 
the NBD1 (green) and its binding to NBD2 (blue) is followed by a slow 
channel opening step (C2 – Open).  This open state becomes destabilized by 
hydrolysis of the ATP bound at the NBD2 and loss of the hydrolysis product, 
inorganic phosphate (Pi).  The disruption of the dimer interface leads to 
channel closure.  From (Gadsby et al., 2006).   
 
Recent, studies with human-murine CFTR chimeras support 
this model, demonstrating that NBD dimerization is led by a 
conformational change in NBD1, and not by simultaneous 
conformation changes of the two NBDs as a dimer (Scott-Ward et 
al., 2007).   Despite the lack of consensus about the mechanism 
that regulates the ATP-dependent gating of CFTR, it is clear that 
the two NBDs are critical and function as distinct modulators of 
CFTR Cl- channel activity.  This is supported by the fact that, in 
contrast to NBD2, NBD1 is a hotspot for CF-causing mutations and 
that equivalent NBD1 mutations within NBD2 have different 
consequences on CFTR (Chen et al., 2001). 
 
2.4.3 CFTR AS A REGULATOR OF OTHER ION CHANNELS 
In CF epithelia, there are several cellular dysfunctions that 
cannot be explained by considering CFTR simply as an apical 
membrane Cl- channel and/or transporter.  In fact, it is accepted 
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that CFTR is a multifunctional and versatile protein.   
In addition to functioning as a Cl- channel, CFTR controls 
the regulation of other ionic channels present in epithelial cells 
such as ENaC, outwardly rectifying Cl- channels (ORCCs), K+ 
channels ROMK (rat distal nephron H+ channel) and the calcium 
(Ca2+)-activated Cl- channels (CaCCs) (McNicholas et al., 1996; 
Schwiebert et al., 1999; Schwiebert et al., 1998a).   
Although the main defect in CF patients is a defective Cl- 
secretion, abnormalities in the transport of other ionic species, Na+ 
for example, are usually detected.  The increase of Na+ absorption 
in CF epithelial is due to the loss of a negative modulation of 
epithelial Na+ channels (ENaC) by CFTR (Stutts et al., 1995). The 
molecular basis for the downregulation of ENaC by CFTR has not 
been identified and several hypotheses have been raised 
(Schwiebert, 1999; Schwiebert et al., 1999).  Some data suggest 
that the absence of CFTR at the plasma membrane leads to 
hyperactivity of ENaC, driven by an interaction between the two 
channels and not by differences in the secretory balance (Guggino 
and Stanton, 2006).  Others have proposed that Cl- transport by 
CFTR regulates ENaC activity (Konig et al., 2001).  
CFTR also regulates a different class of Cl- channels 
activated by cAMP, the outwardly rectifying Cl- channels (ORCC).  
ORCCs are the most abundant channels in epithelial cells and 
were shown to be defective in CF tissues.  CFTR activates ORCCs 
by a mechanism involving ATP release that is CFTR-dependent 
(Schwiebert et al., 1995).  However, the mechanism by which ATP 
is released remains controversial, although NBD1 and the RD 
seem to be required for CFTR to regulate ORCC (Schwiebert et al., 
1998b).   
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CFTR has also been shown to regulate renal outer 
medullary potassium (K+) channels (ROMK) (McNicholas et al., 
1997).  These channels play a major role in K+ homeostasis and 
are expressed in the apical membrane of distal nephron segments 
of the mammalian kidney.  CFTR inhibits ROMK channel activity by 
enhancing its sensitivity to the inhibitory sulfonylurea compound 
glybenclamide (McNicholas et al., 1996).  The mechanism by which 
CFTR inhibits ROMK involves phosphorylation and appears to 
involve NBD1 and the R domain of CFTR (Cahill et al., 2000).   
Moreover, CFTR was also found to play a role in the 
transport of bicarbonate (HCO3-) in the lung, gastrointestinal tract 
and pancreas (Choi et al., 2001a; Reddy and Quinton, 2001).  
Besides acting as a channel regulator, it has also been described 
to play a role in ATP transport, modify the phenomenon of 
exocytosis/endocytosis (Bradbury, 1999) and to regulate the pH of 
intracellular organelles In CF epithelial.   
Additionally, CFTR mediated Cl- secretion might also be 
indirectly activated by stimulation of other, non-CFTR Cl- channels 
that can circumvent a defective CFTR, at least in the airways 
(Amaral and Kunzelmann, 2007).  The alternate, Ca2+-activated Cl- 
channels (CaCCs) can by stimulated via the P2Y2 receptor-
mediated increased intracellular Ca2+ in both human and murine 
airways and may even be up-regulated in CF compared with 
normal airways (Tarran et al., 2002). Some studies have reported 
that a possible explanation of the lack of pathology seen in CF null 
transgenic mice (Grubb and Boucher, 1999) may be du to the fact 
that CaCCs serve as the main pathway for apical Cl- exit in the 
murine airway and consequently the loss of CFTR function is a less 
catastrophic event (Clarke et al., 1994; Grubb et al., 1994). 
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The numerous studies showing that CFTR regulates other 
ion channels as well as being a Cl- channel supports the idea that 
CFTR is a multi-functional and versatile protein.  An epithelial cell 
model summarizing some of the multiple functions of CFTR is 
shown in Figure I.6.   
 
 
Figure I.6 – Multifunctional CFTR.  Epithelial cell model summarizing some of 
the multiple functions of CFTR: 1) Cl- channel function, 2) facilitating of ATP 
release, 3) positive regulation of outwardly rectifying Cl-channels, 4) negative 
regulation of epithelial Na+ channels, 5) regulation of vesicle trafficking, 6) 
regulation of intracellular compartment acidification and protein processing, 
and 7) modulation of ROMK sensitivity to sulfonylureas.  ER – endoplasmic 
reticulum; TGN – trans-Golgi network (Schwiebert et al., 1999).   
 
2.4.4 RESCUING STRATEGIES AND MUTATION-SPECIFIC 
THERAPIES FOR CF  
Cystic fibrosis is a clinically complex disease and 
conventional therapy for CF is largely symptomatic. This has 
fuelled research not only to understand the effects of the various 
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mutations reported but also to correct the basic defect itself.  
Increasing our understanding of the genetic and cellular defects 
that cause CF will certainly lead to an increased possibility for a 
cure.   
 
2.4.5 PHARMACOLOGICAL RESCUE 
Pharmacological rescue relies mostly on mutation-specific 
therapies (Brennan and Geddes, 2004) and can be divided 
according to the class of CFTR mutation targeted (Lim and Zeitlin, 
2001).  These therapies mainly use compounds whose activity is 
specialized in correcting a specific mRNA or protein defect (Kerem, 
2005). 
   
Correction of class I mutations 
These mutations produced mRNA transcripts with 
premature stop codons (PTCs) that are degraded by the non-sense 
mediated decay (NMD) system and fail to produce CFTR protein.  
It was demonstrated that aminoglycosides (G418 or gentamicin) 
are able to suppress those PTCs and to restore the ribosomal 
read-through activity for full-length CFTR (Howard et al., 1996).  
Gentamicin is under clinical trial on patients with CF and CFTR 
stop mutations (Wilschanski et al., 2003). In phase II of clinical trial 
is PTC124 (3-[5-(2-fluorophenyl)-[1,2,4] oxadiazol-3-yl]- benzoic 
acid) an orally bioavailable, non-aminoglycoside compound that 
was specifically developed to induce ribosomes to read through 
premature stop codons, but not normal stop codons (Kerem et al., 
2008).  Preliminary results obtained with this compound 
demonstrated that in a mouse model of stop-mutation-mediated 
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cystic fibrosis, PTC124 generated production of full-length, 
functional CFTR (Kerem et al., 2008).   
 
Correction of class II mutations 
Mutations in this class have a folding defect that results in 
their rapid targeting for degradation by the ERQC.  The most 
common CFTR mutation, F508del, belongs to this class.  
Compounds that promote folding and allow mutant CFTR to 
escape from the ERQC and reach the cell surface will be good 
candidates to repair these mutations.  This group includes 
chemical, molecular or pharmacological chaperones (Pedemonte 
et al., 2005). 
Chemical chaperones like glycerol or TMAO 
(trimethylamine-N-oxide) have been known to stabilize F508del 
(Brown et al., 1996).  Some authors also described that 
phenylbutyrate influences F508del-CFTR folding or trafficking in 
addition to also enhancing transcription (Zeitlin et al., 2002).  
Substituted benzo[c]quinolizinium derivates have also been 
reported to both rescue F508del from the ER and activate its Cl- 
conductance (Dormer et al., 2001).  Other drugs such as DSG 
(deoxyspergualin) can partially restore function to F508del-CFTR 
through the modulation of interaction with molecular chaperones 
(Jiang et al., 1998).   
However, most of these compounds have not yet been 
used in clinical trial due to their inherent toxicity or the mechanism 
by which they act is poorly characterized at the cellular level.  Thus, 
demonstrating the activity of such compounds can generate further 
development of related drugs.  High throughput screens have 
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identified other agents, called correctors, as being able to rescue 
and correct F508del trafficking defect.  Clinical trials are underway 
to determine the clinical efficacy of such compounds (McKone et 
al., 2003).  Currently, corrector 325 (VRT-325), 4a (C4a) and VX-
809 are all under phase II of clinical trial.  All of these compounds 
promote trafficking of F508del-CFTR to the plasma membrane 
(Pedemonte et al., 2005; Van Goor et al., 2006).   
 
Correction of class III mutations 
CFTR mutants in this class have reduced responses to 
regulatory molecules.  The principal representative mutation in this 
class is G551D. Also included is F508del that not only has a 
trafficking defect but also presents a gating impairment (Wang et 
al., 2000).  CFTR potentiators such as genistein and other 
flavonoids can activate Cl- conductance and overcome mutations in 
this class.  Other attempts of pharmacological activation of mutants 
in this class have met little success and correction may require 
protein replacement rather than protein repair (Rubenstein and 
Zeitlin, 1998).  However, potentiator VX-770 has been shown to 
increase CFTR activity in cystic fibrosis patients carrying G551D 
mutation.  This potentiator is already in the clinical trial (phase II) 
and increases the function of CFTR protein that’s already located 
at the cell surface (Van Goor et al., 2009)  
 
Correction of class IV mutations 
Class IV mutants are associated with reduced Cl- 
conductance or abnormal channel gating. Stimulation of CFTR 
conductance can be achieved by either increasing the overall cell 
surface content of these mutants, thus compensating for the 
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reduced conductance or augmenting the existing activity of 
channels with potentiators.   
Compounds like genistein, xanthines and others like 
milrinone and TMAO can stimulate CFTR conductance (Roomans, 
2003).  IBMX (3-isobutyl-1- methylxanthine), an inhibitor of 
phosphodiesterase, also enhances F508del-CFTR function both by 
direct binding and by increasing cAMP cellular levels (Schultz et 
al., 1999).  High-throughput screening has also indentified several 
different potentiators such as VX-532 and VX770 (Van Goor et al., 
2006) (Also described in Corrections of class III mutations, Chapter 
I). 
 
Correction of class V mutations 
This class includes mainly splicing mutations that generate 
both aberrant and correctly spliced mRNAs in variable amounts 
among patients. The major aim for therapy in these cases is to 
increase levels of correctly spliced transcripts.  However, 
modulating the splicing process is very complex and probably 
would need in this case to be tissue specific.   
 
2.4.6 LOW TEMPERATURE  
Soon after the CFTR gene was discovered, F508del-CFTR 
was shown to be a temperature-sensitive mutant.  This mutant, 
when incubated at low temperature (26 ºC), gives rise to the 
appearance of a fully glycosylated protein.  Furthermore, it was 
also shown that this temperature-rescued CFTR mutant functions 
as a Cl- channel at the apical membrane, although at reduced 
levels (Denning et al., 1992).  Even though this observation has no 
therapeutic relevance, this suggests that F508del-CFTR is able of 
General Introduction 
 27 
reach a folding-competent conformation and can be manipulated 
therapeutically.  It should therefore be possible to rescue its folding 
with molecules capable of stabilizing native-like conformations.   
 
2.4.7 GENETIC REVERTANTS 
In addition to the above compounds, genetic manipulation 
has also been described to rescue F508del-CFTR trafficking 
defect.  This consists in the introduction of a second-site mutation 
in cis with the F508del mutation.  
As already mentioned (section 2.1 and 2.3), some of these 
genetic variants are mutations that affect retention/retrieval motifs 
in CFTR responsible for the export of proteins form the ER.  
Arginine-framed tripeptide (AFTs) are involved in the retrieval 
mechanism of misfolded CFTR proteins through direct association 
of the AFT-sequences to COPI coated vesicles in early and cis 
Golgi compartments (Wendeler et al., 2007). Their are four AFTs in 
CFTR: R29 (N-terminal cytoplasmic domain), R516 (NBD1), R555 
(NBD1) and R766 (R domain) (Figure I.7). 
 
 
Figure I.7 – Schematic representation of CFTR protein indicating the 
approximate localization of the four arginine-framed tripeptides motifs (Chang 
et al., 1999). 
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Consequently, the simultaneous substitution of all four 
arginines (R) by lysine (K) residues (R29K + R516K + R555K + 
R766K) allows nascent F508del-CFTR to mature, with an efficiency 
of about one-third of that of wt-CFTR, and to generate functional Cl- 
channels at the cell surface (Chang et al., 1999).  It is still unclear 
whether the rescue mechanism relies on a conformation change 
due to replacement of the arginines with smaller lysine residues or 
on the removal of the specific ER retention motif.  Recent studies 
demonstrated that when F508del-CFTR is co-expressed with 
truncated N-terminal constructs functional rescue is observed 
(Owsianik et al., 2003). Moreover, when the AFTs of the truncated 
construct were mutated, the revertant effect is strongly impaired.  
This likely occurs due to the concealment of the AFTs and the 
consequent recognition of the ERQC allowing F508del-CFTR to 
escape (Owsianik et al., 2003).  Therefore, it seems that for 
F508del-CFTR, masking AFT retention signals is more accessible 
then for wt-CFTR.   
 
3. CFTR STRUCTURE  
As previously mentioned, CFTR is a multidomain protein 
containing 1480 aa residues and functioning as a cAMP-activated 
and phosphorylation-regulated chloride (Cl-) channel at the apical 
membrane of epithelial cells.  CFTR, or ABCC7, belongs to the 
ATP-binding cassette (ABC) transporter superfamily. The ABC 
transporters are a large family of proteins involved in active 
transport of various metabolites, peptides or ions across biological 
membranes of Prokaryotes and Eukaryotes.  There are more than 
fifty members in this protein superfamily, including α-mating factor 
transporter of yeast (ST6), responsible for the secretion of a mating 
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factor in yeast; P-glycoprotein (P-gP), that confers resistance to 
chemotherapeutic drugs; TAP1 and TAP2, associated with antigen 
presentation 1 and 2, just to name few.   
CFTR structure, shown in Figure I.8 resembles that of a 
typical ABC transporter with two membrane-spanning domains 
(MSDs) and two nucleotide-binding domains (NBD1 and NBD2). In 
contrast to most ABC transporters, CFTR also contains a unique 
and large regulatory domain (RD) where multiple phosphorylation 
occurs (Riordan et al., 1989; Sheppard and Welsh, 1999). 
 
 
Figure I.8 – Model showing domain structure of CFTR. MSD, membrane-
spanning domain; NBD, nucleotide-binding domain; R, regulatory domain; 
PKA, Cyclic adenosine monophosphate (cAMP)-dependent protein kinase 
(Sheppard and Welsh, 1999). 
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3.1 CFTR FUNCTIONAL DOMAINS 
MSDS 
The MSDs of ABC-transporters share a similar topological 
organization although they have different primary sequences.  This 
explains why these proteins transport so many different substances 
(Locher et al., 2002). 
CFTR is anchored at the apical membrane of epithelial cells 
by twelve hydrophobic segments (TM1-TM12) that constitute its 
two transmembranar domains and form the pore of the channel 
(Chang et al., 1994). The most conserved TM motifs in CFTR are 
TM6 and TM12, that line the pore of the channel (Sheppard and 
Welsh, 1999).  TM6 has also been found to play an important role 
in the properties of the pore (Ge et al., 2004). The transmembranar 
segments are linked by six extracellular (ECL) and four intracellular 
loops (ICL), the fourth of which possesses two consensus N-
glycosylation sites (N894 and N900).  ICL sequences seem to 
ensure correct interdomain interactions, such as those occurring 
between MSDs and NBDs, being important for processing and 
function (Chen et al., 2001; Sheppard and Welsh, 1999).   
NBDs 
The NBDs have significant sequence conservation 
throughout the ABC family and are characterized by the presence 
of three conserved motifs: Walker A, Walker B and the ABC-
signature motif, LSGGQ (C motif), located just upstream of Walker 
B (Schneider and Hunke, 1998).  These consensus motifs are 
essential for ATP binding and hydrolysis which allows NBDs to act 
as catalysts of ATPase reactions.  NBDs in CFTR, as in other ABC 
proteins, are expected to assemble in a head-to-tail orientation 
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(dimer) thus creating two ATP binding sites in the dimer interface 
rather than in each NBD individually.  Each site is formed by the 
Walker A and B of one NBD and the signature motif of the other 
NBD (Lewis et al., 2004). Despite the apparent symmetry in the 2 
NBD – 2 MSD structure of CFTR, the similarity between the two 
NBDs is only about 29% (Riordan et al., 1989).  These differences 
create an asymmetry in the binding sites, with one being a stable 
ATP-binding site at which hydrolysis does not occur (site I) and the 
other site the hydrolytic site (site II) (Riordan, 2005).  This suggests 
that the NBDs have the ability to hydrolyze ATP and to regulate 
channel gating but that the two NBDs are not functionally 
equivalent (Sheppard and Welsh, 1999).   
R-domain 
CFTR distinguishable feature from other ABC transporters 
is the R domain.  This highly charged domain has several predicted 
phosphorylation sites for PKA (cAMP-dependent protein kinase) 
and PKC (protein kinase C).  For PKA it includes eight serines 
(S660, S686, S700, S712, S737, S768, S795 and S813) and one 
threonine (T788) residue.  For PKC, consensus sites are serine 
residues S686 and S700 (Sheppard and Welsh, 1999).  
Independently of its phosphorylation status, the RD is mostly 
unstructured.  Its regulatory activity upon the NBDs and the 
channel pore is thought to be mediated by NBD: RD interactions, 
which are regulated by the RD phosphorylation status (Baker et al., 
2007; Ostedgaard et al., 2001).   
 
3.2 HUMAN AND MOUSE CFTR – NBD1 STRUCTURE 
It has been proposed that the primary effect of the F508del 
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mutation is to cause misfolding of NBD1, which leads to aberrant 
transport and ultimately targeting proteolytic degradation of CFTR 
(Thomas et al., 1992).  To better understand how the ERQC is 
recognizing F508del-CFTR and thus fully elucidate the molecular 
basis of CF (and ultimately to achieve drug-designed therapy) it is 
nevertheless important to understand the exact nature of CFTR 
structure and (mis)folding.  High-resolution structures of murine (m) 
and human (h) NBD1 have provided invaluable information about 
the structure of NBD1 (Lewis et al., 2004; Lewis et al., 2005).   
These NBDs were shown to have similar structures to that 
of other ABCs transporters with a central α/β F1-type core 
containing sequences for Walker A and B, and antiparallel β-sheet 
(ABCβ) and a α-helical (ABCα) subdomain where the signature 
sequence lies (Lewis et al., 2004).  The main differences to this 
basic structure (Figure I.9) consist in the insertion of two short α-
helices between the two β-strands (S1 and S2), in an added long 
α-helix in the C-terminal, in the deletion of a segment between β-
strands S4 and S6 that typically consists of a β-strands and a α-
helix truncation between helices H3 and H4 (Lewis et al., 2004).   
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Figure I.9 – (A) Stereo ribbon diagram of mNBD1.  ATP is shown in ball and 
stick representation.  The F1-ATP-binding core subdomain is shown in gold, 
the ABC α-subdomain in cyan, and the ABC β-subdomain in green.  The 
dotted red line indicates residues missing from the model.  Figure I.9A. Right: 
the same structure rotated 80º toward the viewer.  (B) Topology diagram of 
mNBD1.  The subdomains are colored as in A.  Regions that are different 
from previous ABC structures are shown in gray.  From (Lewis et al., 2004).    
 
 
The added segments, termed regulatory insertion (RI) and 
regulatory extension (RE), are quite flexible and contain serine 
residues that can be phosphorylated in vitro. Both the RE and RI 
segments have been suggested to be conformationally dynamic, 
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namely upon phosphorylation possibly to allow formation of the 
NBD1/NBD2 ATP-sandwich for channel gating (Lewis et al., 2004; 
Lewis et al., 2005).    
In the mNBD1 crystal, F508 was found to be placed at the 
start of a loop between helices H3 and H4.  In the heterodimer 
model of the two NBDs, this site is distant from either ATP 
suggesting that F508 is unlikely to affect ATP binding directly and 
thus have a limited impact on either NBD1 or the NBD1: NBD2 
dimer.  In fact, homology models indicate that the F508 surface is 
at the interface with MSD1, suggesting a role in NBD1: MSD 
interactions.  These interactions would be important in stabilizing 
the architecture of the full-length protein (Lewis et al., 2004).   
The hNBD1 structures closely resemble that of mNBD1, 
with the exception of the RE and RI (Lewis et al., 2005).  The 
human F508-NBD1 structures available have incorporated a series 
of mutation to promote domain solubilisation and, hence 
crystallization.  The structures have 7 mutations (F409L, F429S, 
F433L, G550E, R553Q, R555K and H667R), 3 mutations (F429S, 
F494N, Q636R) or 2 mutations (F504N, Q646R) (PDB ID codes 
2BBO, 2BBS or 2BBT respectively).  These mutations were later 
shown to rescue the cell-surface expression and function of 
F508del-CFTR (Pissarra et al., 2008).  Thus, the available crystal 
structure of human F508del-NBD1 might correspond to a partially 
corrected conformation of this domain. 
 
3.3 COMPLETE CFTR MODELS  
There has been some controversy about CFTR quaternary 
structure.  Some studies on cellular and purified CFTR defend that 
the CFTR pore assembles as a monomer (Bear et al., 1992).  
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Others support the notion that monomer CFTR is the minimal 
functional unit, based on low resolution studies and biochemical 
and electrophysiological readings at the single channel level 
(Ramjeesingh et al., 2001; Rosenberg et al., 2004).  However, 
several other studies have been published supporting the idea that 
CFR assembles in vivo as a homodimer (Schillers et al., 2004; 
Zerhusen et al., 1999).  According to these studies, dimerization 
would occur possibly through the C-terminal PDZ motif and would 
be regulated by PKA phosphorylation (Ramjeesingh et al., 2003; 
Schillers et al., 2004).   
Although high-resolution structures of human and murine 
NBD1 has been determined, progression towards a structure 
determination of the whole CFTR protein as been hindered by the 
lack of abundant sources for its purification and its limited solubility 
(Riordan, 1993; Rosenberg et al., 2004).  Among eukaryotic ABC 
proteins, low resolution structures have been determined for P-
glycoprotein and MRP1 (Higgins et al., 1997; Rosenberg et al., 
2005).  P-glycoprotein has enabled the visualization of the major 
shape changes of the MSDs and as a consequence of the NBDs.  
Although potential analogies between domain interaction between 
P-glycoprotein and CFTR are possible, CFTR structure still needs 
to be determined.  Recently, a 3D structure of CFTR has been 
placed forward based on the Sav1866 structure (Serohijos et al., 
2008).  Indeed, high-resolution structures have been determined 
for several bacterial ABC transporters namely, BtuCD, MsbA, 
Sav1866, ModBC (Dawson and Locher, 2006; Hollenstein et al., 
2007; Locher et al., 2002).  These structures provided important 
new insights into the mechanisms by which these proteins 
accomplish transmembrane translocation of their substrates.  
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Although CFTR functions has a channel rather than a transporter, 
sequence and biochemical similarities between Sav1866 and 
CFTR suggest that there are likely to have a very similar structure 
(Serohijos et al., 2008).  This allowed the production of a 3D model 
of CFTR (Figure I.10) based on molecular modeling revealing 
important features of the interfaces between the NBDs and MSDs.   
 
Figure I.10 – Theoretical model of CFTR structure. (A) Schema of CFTR 
primary structure two NBDs (NBD1 and NBD2), two MSDs (MSD1 and 
MSD2), and a RD.  Each MSD contains two cytoplasmic loops (CL) that form 
interfaces with the NBDs.  (B) Homology model of CFTR constructed from 
Sav1866 exporter, where the domains are colored as in the schema.  The RD 
was approximated by constructing an ensemble of dynamically accessible 
conformations derived from ab initio folding.  From (Serohijos et al., 2008).   
 
This model establishes an intramolecular contact between 
F508 residue and residues at ICL4.  This data implies that the most 
critical contact in conformational maturation during biosynthesis, 
which is precluded by the F508del mutation, is probably between a 
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site containing that F508 residue on the surface of the N-terminal 
NBD and a cytoplasmic loop in the C-terminal MSD (see Figure 
I.10A).  However, the corresponding crossing-over between NBD2 
and MSD1 seems to be less crucial to maturation of the protein, 
possibly due to the fact that NBD2 is the last portion of the 
polypeptide to be translated and thus allowing for a 
posttranslationally incorporation into the complete structure of the 
protein (Serohijos et al., 2008).    
A better understanding of the molecular basis for 
pathogenesis in patients harboring disease-causing mutations is 
thus still dependent in the availability of the exact structure of 
CFTR. 
 
3.4 Aims 
The present doctoral work aimed at dissecting particular 
aspects of in vivo folding of full-length CFTR by mutagenesis 
coupled to biochemical, cell biology and functional approaches, so 
as to validate existing structural models of full-length CFTR 
obtained by computational methods.  
Towards this overall goal, this work was centered on the 
two following specific objectives:  
1. To use a cross-species comparative approach, by 
evaluating the in vivo folding of human (h) / mouse (m) 
chimeric CFTR proteins, indirectly assessed by 
processing. Also, to gain insight into the structural 
impact of regions of divergence responsible for possible 
processing defect(s) observed in the hmCFTR 
chimeras by studying processing (and other properties) 
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of various point mutants in these regions. 
2. To determine the impact on the in vivo folding 
(assessed through processing) of removing the RI and 
RE from wt- and F508del-CFTR. Also to assess the 
effect of revertant mutations (R1070W and G550E) on 
processing of these ΔRI and ΔRE CFTR variants. 
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II - MATERIALS AND METHOD 
1. CLONING CHIMERIC CDNAS INTO PNUT EXPRESSION 
VECTOR 
1.1 BACTERIAL STRAIN 
In the present work, the XL1-Blue bacterial strain was used.  
This strain has the following genotype: supE44, hsdR17, recA1, 
endA1, gyrA46, thi relA1, lac F’[proAB+ lacIq lacZ∆M15::Tnt10 
(Tetr)] (Stratagene, La Jolla, CA, USA).  XL1-Blue cells are 
endonuclease (endA) deficient, which greatly improves the quality 
of miniprep DNA, and are recombination (recA) deficient, improving 
insert stability. The hsdR mutation prevents the cleavage of cloned 
DNA by the EcoK endonuclease system. The lacIqZΔM15 gene on 
the F´ episome allows blue-white color screening.   
 
1.2 PLASMIDS AND CDNAS 
Human-murine CFTR chimeras that were previously 
generated (Scott-Ward et al., 2007) (by replacing NBD1, NBD2 and 
the R domain in a hCFTR protein backbone with the equivalent 
regions of mCFTR) cloned into the SalI site of pCMV mammalian 
expression vector for or the SmaI site of the pFLMCFTR (mouse 
CFTR) were kindly provided by Dr. Chris Boyd, University of 
Edinburgh, Edinburgh, UK.   
The pNUT vector is a high-expression vector that contains a 
SmaI site, immediately downstream the mouse metallothionien  
promoter (MTp) and upstream the human growth hormone 
polyadenylation sequence (Tabcharani et al., 1991).  The CFTR 
coding sequence is inserted into the Smal site in the sense 
orientation. This vector contains a SV40 early promoter (SVp) that 
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controls the dihydrofolate reductase (DHFR) gene, that enables 
selection and promotes transgene amplification (Appendix I). 
 
1.3 COMPETENT BACTERIA PREPARATION  
Competent bacteria preparation was performed according 
to the technique described by Hanrahan (Hanrahan, 1985).  Cells 
were plated on solid LB media (2 % (w/v) bactotriptone, 0.5 % (w/v) 
yeast bactoextract, 10 mM NaCl, 1.5 % (w/v) agar).  Liquid medium 
was inoculated with a single colony and incubated at 37 °C with 
constant agitation (220 rpm) to a concentration of approximately 4-
7X107 bacteria/ml (determined by A550 between 0,45-0,55).  
Bacteria were left on ice for 15 min and then centrifuged at 3000 
rpm for 15 min at 4 °C.  The pellet was resuspended in a third of 
the initial volume of RF1 buffer (100 mM RbCl, 50 mM MnCl2, 30 
mM KCH3COO pH7.5, 10 mM CaCl2, 15 % (w/v) glycerol, pH 5.8).  
The suspension was left on ice for 15 min and then centrifuge at 
3000 rpm for 15 min at 4 °C.  The pellet was resuspended in 1/12.5 
of the initial volume of buffer RF2 (10 mM MOPS, 10 mM RbCl, 75 
mM CaCl2, 15% (w/v) glycerol, pH 6.8).  After a further incubation 
on ice for 15min, tubes containing 200 µl aliquots were rapidly 
frozen in liquid nitrogen and stored at -80 °C. 
 
1.4 HYDROLYSIS OF CHIMERIC CDNA AND VECTOR 
Hydrolysis of the chimeric cDNA with restriction 
endonucleases was performed in the appropriate buffer at the 
temperature recommended by the manufacturer.  The Sall enzyme 
(originating cohesive ends) was used for all human-murine 
chimeric cDNA and SmaI or XmaI (originating blunt ends) was 
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used for the murine chimeric cDNA and pNUT vector.  The 
restriction enzymes used were supplied by New England BioLabs 
(Beverly, MA, USA) or Boehringer Ingelheim (Ingelheim, Germany).  
An appropriate quantity of DNA (1-10 µg) was hydrolyzed in a 
suitable volume (usually 5-50 µl) containing the respective buffer 
and 1U of enzyme per µg of DNA.  The reaction was carried out at 
the recommended temperature for 1-24 h, depending on the 
amount of DNA to be hydrolyzed.  Larger quantities of DNA (> 1 
µg) were always hydrolyzed overnight.  Following hydrolysis, the 
restriction endonucleases were heat-inactivated by incubation at 
60-70 °C for 15 min.  The digested cDNA fragments were purified 
by electrophoresis of the samples at 75 V in 0.8 % (w/v) low 
melting agarose/1×TAE buffer for a few hours.  Gels were 
visualized on a mid-range UV transilluminator (UviTec, Topac, St-
Hingham, MA, USA) and the desired fragment excised using a 
sterile scalpel blade.  Excision was performed as quickly as 
possible to avoid nicking of DNA by UV radiation.  Care was taken 
to ensure that the minimum amount of agarose was excised with 
the fragment of DNA of interest.  Each DNA fragment was isolated 
from the excised gel slice by the “Squeeze and Freeze” method.  
The last consist of separating the DNA from the agarose with a 
10min centrifugation at 14000 rpm followed by the addition of 1/10 
volume of a 3 M solution of NaCH3COO (pH 5.2) and 2.5 volume of 
100 % ethanol (EtOH). After a 10 min centrifugation (14000 rpm) 
the supernatant was discarded and the pellet was washed with 900 
µl of 70 % (v/v) EtOH.  Once again, a last centrifugation was 
carried out for 3 min and the pellet resuspended in 15 µl EB buffer 
(10 mM tris-HCl, pH 8.5) after briefly drying all residual liquid at 
room temperature.    
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1.5 DE-PHOSPHORYLATION OF CLONING VECTOR 
Calf intestinal alkaline phosphatase, CIP (Amersham 
Bioscience, Piscataway, CA, USA) was used to dephosphorylate 
the 5’ ends of the pNUT vector prior to ligation reaction.  Each 
monomer of CIP carries two atoms of zinc that are essential for the 
activity of the enzyme (Sambrook et al., 1989).  Dephosphorylation 
of the vector ends facilitates ligation with inserts because it 
minimizes in vivo re-circularization of the vector.  Linearized DNA 
was dephosphorylated by incubation with 1U of CIP per µg DNA 
and reaction buffer (Amersham Bioscience) in a suitable volume of 
sterile water at 37 °C for 1 hour.  The CIP was then inactivated by 
incubation at 75 °C for 10 min. 
 
1.6 LIGATION OF A SALI ADAPTER TO CLONING VECTOR 
In order to make the 5' overhangs of the human-murine 
chimeras, resulting from SalI-hydrolysis (see above) to the SmaI-
compatible (i.e., blunt), we designed an adaptor (5’-
TCGACCCGGG-3’) to ligate to the dephosphorylated pNUT vector.  
Synthetic linkers or adaptors are an equimolar mixture of self-
complementary, chemically synthesized oligomers that can form 
blunt – or cohesive – ended duplexes (Sambrook et al., 1989).  The 
SalI adapter was incubated with the previously dephosphorylated 
pNUT at a 10-fold molar excess, in the presence of T4 DNA ligase 
(New England BioLabs, Beverly, MA, USA) according to the 
manufacturer’s instructions.  The reaction was carried out at 16 °C 
overnight and then passed through a QIAquick column (Qiagen, 
Hilden, Germany). 
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1.7 LIGATION OF THE CHIMERIC CDNAS BY T4 DNA LIGASE 
WITH THE LINEARISED RECIPIENT VECTOR 
DNA fragments from the same or different sources can be 
covalently joined (ligated) with T4 DNA ligase.  The ligated DNA 
can then be transformed and transfected.  The hmCFTR cDNAs 
were ligated with the dephosphorylated linearized pNUT – SalI 
adaptor construction at a ratio of 3 (insert): 1 (vector) using T4 DNA 
ligase (New England BioLabs, Beverly, MA, USA) according to the 
manufacturer’s instructions. The reaction was performed overnight 
at 16 °C.  The optimal ratio of vector: insert DNA, and their 
absolute concentrations in the ligation reaction, depend on the type 
of ligation (i.e. cohesive or blunt-end).  Also, it is important to note 
that if the concentration of DNA is too high, there will be an 
increased probability that two or more fragments insert into the 
resulting recombinant vector.  If the concentration of DNA is too 
low, few of the colonies/plaques resulting from bacterial 
transformation will have inserts (being mostly be re-circularized 
vectors).  
 
1.8 TRANSFORMATION 
Bacterial transformation is the process by which bacterial 
cells take up naked DNA molecules. If the foreign DNA has an 
origin of replication recognized by the host cell DNA polymerases, 
the bacteria will replicate the foreign DNA.  E. coli cells (XL1B 
strain) were made competent as described above (see section 1.3, 
chapter II) the calcium chloride method.  An aliquot (10 µl) of each 
ligation reaction sample (hmCFTR or mCFTR cDNAs with the 
pNUT vector) was added to 200  µl of XL1B competent cells.  This 
mixture was placed on ice for 30 min and then heat-shock (42 ºC) 
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was applied for 3 min to allow the uptake of the plasmids.  To allow 
activation of the ampicillin (Amp) resistant gene within the plasmid, 
the cells were incubated for 1 h at 37 °C with continuous shaking at 
250 rpm.  The mixture was then spread evenly across the surface 
of fresh LB-agar plates with 100 µg/ml Amp using a sterile bent 
glass rod.  Plates were air-dried for 5 min until the recovery media 
had absorbed into the agar then inverted, and incubated at 37 °C 
for 12-16 h.  Colonies were picked from each plate and used to 
inoculate 3 ml of LB medium supplemented with 100 µg/ml Amp 
and grown overnight at 37 °C with continuous shaking at 250 rpm.  
DNA was then extracted and isolated from the bacterial culture. 
 
1.9 PLASMID DNA EXTRACTION AND PRELIMINARY ANALYSIS 
BY PCR AND ENZYME DIGESTION TO ASSESS FOR THE 
PRESENCE OF THE RESPECTIVE CFTR FRAGMENT 
Following extraction from the bacterial clones using the 
Plasmid Mini kit (Qiagen, Hilden, Germany), plasmids were 
subjected to preliminary analysis on agarose gel after hydrolysis 
with two restrictions enzymes (BamHI/KpnI, Amersham Bioscience, 
GE healthcare life sciences, Uppsala, Sweden) to assess for the 
presence of the respective CFTR fragment. This can be 
accomplished because the hydrolysis will originate fragments of 
different sizes, which will determine if the CFTR fragments are 
correctly inserted. The first enzyme (BamHI) hydrolises 3 times in 
the human cDNA and twice in the murine cDNA whereas KpnI only 
cuts once in the pNUT vector.  Briefly, an appropriate quantity of 
DNA was hydrolyzed in a suitable volume (usually 30 µl) containing 
Universal buffer (Stratagene, California, USA) and 1U of BamHI 
per µg of DNA.  The reaction was carried out first at 30 °C for 1 h 
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30 min, then at 37 °C for another 1 h 30 min after the addition of 1U 
of KpnI and 1 µl of Universal buffer (Stratagene, California, USA). 
Following hydrolysis, the digested cDNA fragments were visualized 
on 0.8 % (w/v) agarose gel prepared in TBE.   
In parallel, the presence of the constructs was tested with 
the help of the polymerase chain reaction (PCR).  The colonies 
resulting form the different ligations were used as a template in a 
reaction solution containing, for a final volume of 50 µl, 1x PCR 
buffer I (supplied with AmpliTaq®, Applied Biosystems, Foster City, 
CA, USA), 10 pmol of each primer, 200 µM each dNTP, 1.5 U 
AmpliTaq® DNA Polymerase (Applied Biosystems). Reactions 
were carried out using an OMN-E thermocycler (Thermo-Hybaid, 
Woburn, MA, USA) with the “hot lid” on. Specificity of PCR 
products was confirmed by sizing on agarose gels. The use of 
primer A1Reverse (5’–GACCTCTGCATGGTCTCTCG–3’) and 
G1R (5’–GCTGCTCTGAAAGAGGAGAC–3’) allows visualization 
for the presence or absence of the CFTR fragments.  This pair of 
primers allows part of the amplification of a CFTR fragment in 
addition to the N-terminal of the pNUT.  
 
1.10 SEQUENCING OF NOVEL PLASMIDS 
All pNUT hmCFTR cDNA constructs that exhibit an extra 
band of appropriate size in agarose gel analysis or that are positive 
for the PCR or exhibit the desired pattern when digested with 
BamHI/KpnI were subjected to sequencing using the ABI Prism® 
3100 Genetic Analyzer (Applied Biosystems) using the Big 
Dye®Terminator v1.1 sequencing kit (Applied Biosystems, 
Norwalk, CA, USA). 
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2. PRODUCTION OF CFTR VARIANTS BY SITE-DIRECTED 
MUTAGENESIS 
The QuickChange® mutagenesis kit (Stratagene, LaJolla, 
CA, USA) was used to introduce mutations into pNUT-wt-CFTR 
clone 12b and pNUT-wt-CFTR clone 114c and to delete the 
regulatory region (∆RE) and insertion (∆RI).  Each mutation was 
verified by sequencing (see section 1.10 of Chapter II).   Cell lines 
expressing different mutations are referred to as follows: E527Q, 
E528Q, S531T, K536Q, I539T and K584E for clone 12b (NBD1) 
and T1263I, P1290T, K1302Q, Y1307N, Q1309D, S1311K, 
R1325K, V1338T, C1344Y, L1367I, D1394G and E1409D for clone 
114c (NBD2).  For the deletion of the regulatory region (∆RE) and 
regulatory extension (∆RI), additional mutations were inserted in cis 
namely R1070W and G550E for each.  Each reaction was made 
possible by the use of complementary pairs of custom designed 
HPLC-purified mutagenic primers (MWG – Biotec AG, Ebersberg, 
Germany and Thermo Electron Corporation, Waltham, MA, USA) 
shown in Table II.I. 
Materials and Methods 
 49 
Table II.I: Custom designed primers used to introduce or remove mutations into pNUT-CFTR cDNA.  The oligonucleotide substitutions 
or deletions (∆RE and ∆RI) are underlined. 
 
Name of Forward Primer Sequence 5’  3’ 
E527Q GCATGCCAACTACAGGAGGACATCTCC 
E528Q TGCCAACTAGAACAGGACATCTCCAAG 
S531T CAACTAGAAGAGGACATCACCAAGTTTGCAGAGAAAGAC 
K536Q GACATCTCCAAGTTTGCAGAGCAAGACAATATAGTTCTTGG 
I539T GCAGAGAAAGACAATACAGTTCTTGGAGAAGG 
L581F CCTTTTGGATACCTAGATGTTTTTACAGAAAAAGAAATATTTGAAAGC 
L581F-K584E CCTTTTGGATACCTAGATGTTTTTACAGAAGAAGAAATATTTGAAAGC 
K584E CCTTTTGGATACCTAGATGTTTTAACAGAAGAAGAAATATTTGAAAGC 
T1263I GAGACTACTGAACATTGAAGGAGAAATCC 
P1290T GGAGGAAAGCCTTTGGAGTGATAACACAGAAAGTATTTATTTTTTCT 
K1302Q CTGGAACATTTAGACAAAACTTGGATCCC 
Y1307N GAAAAAACTTGGATCCCAATGAACAGTGGAGTGATC 
Q1309D GGATCCCTATGAAAAATGGAGTGATCAAG 
S1311K GATCCCTATGAACAGTGGAAAGATCAAGAAATATGGAAAG 
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Name of Forward Primer Sequence 5’  3’ 
R1325K GAGGTTGGGCTCAAGTCTGTGATAGAAC 
V1338T GGGAAGCTTGACTTTACCCTTGTGGATGGGGGC 
C1344Y GTGGATGGGGGCTATGTCCTAAGCCATG 
L1367I CTCAGTAAGGCGAAGATCATACTGCTTGATGAACCCAG 
D1394G CAAGCATTTGCTGGTTGCACAGTAATTC 
E1409D GGATAGAAGCAATGCTGGATTGCCAACAATTTTTGGTC 
∆RE GGGATGTGATTCTTTCGACCAATTT∆REGATGCTCCTGTCTCCTGGACAGAAAC 
∆RI GGGATTTGGGGAATTATTTGAGAAA∆RITCTTCAGTAATTT CTCACTTCTTGG 
R1070W CTTCGTGCCTTCGGATGGCAGCCTTACTTTG 
G550E GGAATCACACTGAGTGAAGGTCAACGAGCAAG 
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In vitro site-directed mutagenesis is an invaluable 
technique for studying protein structure-function relationships and 
for identifying critical intra-molecular regions or aa. We used site-
directed mutagenesis because it allows site-specific mutation in 
any double-stranded (ds) plasmid.  Briefly, this procedure uses a 
supercoiled dsDNA vector with an insert of interest and two 
synthetic oligonucleotide primers (reverse complement of each 
other), each containing the desired mutation.  For each mutant, a 
PCR reaction was set up with 2.5 U of pfuTurbo DNA polymerase 
(Stratagene, LaJolla, CA, USA) or KOD Hot Start DNA polymerase 
(Calbiochem, Novabiochem, Novagen, Merck) and cycling 
parameters set according to manufacturer’s instructions.  
Amplification was confirmed by agarose gel electrophoresis and 
the resultant nick-containing mutant plasmids were digested with 
DpnI (Stratagene, LaJolla, CA, USA) (target sequence: 5’- 
Gm6ATC – 3’), specific for methylated and hemimethylated DNA. 
This allows destruction of template, thus selecting for mutation 
containing synthesized DNA.  The nicked vector DNA incorporating 
the desired mutation was then transformed into XL1-Blue 
competent cells (see section 1.8, Chapter II).   The presence of 
each mutation was verified by automatic DNA sequencing (see 
section 1.10, Chapter II).   
 
3. CELLS, CULTURE CONDITIONS AND TRANSFECTIONS 
3.1 MAMMALIAN CELL LINES  
The Human Embryonic Kidney (HEK293) is an immortalized 
cell line derived from a clone of primary human embryonic kidney 
cell transformed with sheared adonevirus 5 DNA (Graham et al., 
1977).  Although this cell line was originally assumed to derive from 
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a fibroblastic, endothelial or epithelial cell, all of which are abundant 
in the kidney, it has been shown that they express several 
neurofilament proteins and may have originated from a rare 
neuronal progenitor cell in the kidney cell culture (Shaw et al., 
2002).  HEK 293 cells are commonly used, as they are easy to 
grow in culture and to transfect.   
The Baby Hamster Kidney (BHK 21) cell line is a quasi-
diploid established line of Syrian hamster cells, descendent from a 
clone of an unusually rapidly growing primary culture of new-born 
hamster kidney tissue (Stocker and MacPherson, 1964).  Usually 
described as fibroblastic, they are also expressing smooth muscle 
desmin, an intermediate filament protein. This cell line, normally 
abbreviated to BHK, is also widely used in cell biochemistry and 
physiology studies as they are easy to grow and transfect.   
 
3.2 CELL CULTURE CONDITIONS  
 All eukaryotic cell handling was performed in sterile 
conditions in a P2 laminar flow hood (Biohazard, Braun 2.4 micro, 
Applitek, Belgium).  Cells were grown at 37 °C in a humidified 
atmosphere of 5 % (v/v) CO2 in a sterile incubator (Leec CO2 
incubator, Ontario, Canada).    BHK and HEK293 cells were 
cultured in a 1:1 mixture of Dulbecco’s Modified Eagle Medium 
(DMEM) and Ham’s F-12 nutrient medium supplemented with 5 % 
(v/v) foetal bovine serum (FBS) (Invitrogen, USA) and only stable 
transfectants ere maintained in the presence of 500µM 
methotrexate.  In some experiments, BHK cells expressing 
F508del-CFTR or other CFTR mutants were cultured at 26 °C for 
72 h to overcome the processing defect of the mutations and 
promote their delivery to the cell membrane (Denning et al., 1992).    
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3.3 TRANSFECTIONS 
Transient expression of wild-type and chimeric CFTRs in 
HEK 293 cells was performed using the Lipofectin® reagent 
(Invitogen, USA).  Cells were transfected with 3 µg of cDNA for all 
CFTR variants.  48 h after transfection, we extracted total protein 
was extracted and CFTR expression assayed by Western blotting 
(WB) (see section 4.3, Chapter II).  
 To generate cell lines stably expressing high levels of CFTR 
variants, BHK cells were transfected with CFTR cDNAs (3 µg) 
using Lipofectin® and selected for stable transfection using 
methotrexate (500 µM). For each CFTR variant, 10 BHK clones 
were isolated and analysed by WB. Of these, the clone expressing 
the highest level of CFTR protein was selected for further analyses, 
ensuring that CFTR expression levels among the different CFTR 
variants were equivalent.  
 
4. CFTR PROTEIN ANALYSIS  
4.1 TOTAL PROTEIN EXTRACTS  
 For Western blot (WB), protein extracts were prepared 
using cell lysis with Laemmli sample buffer (1.5 % (w/v) SDS; 10 % 
(v/v) glycerol; 0.001 % (w/v) bromophenol blue; 0.5 mM 
dithiotreitol; 31.25 mM Tris (pH 6.8)).  DNA was sheared by 
passing the sample first through a 22G and then a 27G needle until 
viscosity decreased or samples were treated with 1 µl benzonase® 
nuclease (5U) (Sigma, Aldrich).   This endonuclease is a 
genetically engineered from Serratia marcescens and degrades all 
forms of DNA and RNA.   
 
Chapter II 
 54 
4.2 PROTEIN QUANTIFICATION BY THE MODIFIED MICRO-LOWRY 
METHOD 
 The Lowry method is one of the most widely used assays 
for protein quantification (Lowry et al., 1951).  The Lowry protein 
assay is based on the reaction of Cu2+, produced by the 
coordination of the peptide bonds, and Folin’s reagent (a mixture of 
phosphotungstric acid and phosphomolybdic acid in phenol) 
detection of aromatic residues.  The concentration of the reduced 
Folin reagent is assessed by absorbance 750 nm (A750) 
measurement.  
Total cell extracts were diluted in water and proteins were 
solubilized with 0.015 % (w/v) sodium deoxycholate.  Samples 
were then precipitated with 7 % (w/v) trichloroacetic acid and 
centrifuged at 14000 rpm for 5 min.  The supernatant was removed 
by suction and the pellet was resuspended in water and incubated 
with freshly made solution A (0.625 % (w/v) Na2CO3, 0.1 % (w/v) 
Na/K tartarate, 0.5 % (w/v) CuSO4, 1.25 % (w/v) SDS, 100 mM 
NaOH).  Finally, solution B (Folin-Ciocalteau reagent diluted 5-fold 
in water) was added to each sample.  After an incubation of 30 min, 
A750 was measured and protein concentration was determined 
using a regression equation established with BSA standards 
(BioRad, Hercules, CA, USA) processed in parallel with the 
samples.   
  
4.3 WESTERN BLOT ANALYSIS 
Protein extracts that were previously quantified by the 
Lowry method (see above) were separated by SDS-polyacrylamide 
gel electrophoreses (PAGE) on 7 % (w/v) mini-gel (Mini-Protean® 
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II, BioRad, Hercules, CA, USA) and electrotransfered (Mini trans-
Blot® BioRad, Hercules, CA, USA) onto nitrocellulose filters 
(Schleicher & Schuell, Dassel, Germany).  After blocking with 5 % 
(w/v) skimmed milk (Molico, Nestle, Vevey, Switzerland) in PBS 
containing 0.1 % (v/v) Tween (PBST) for 2 h, the filters were 
probed with anti-CFTR antibody M3A7 (Chemicon, Temecula, CA, 
USA) diluted 1:3000 or the anti-CFTR 596 antibody (CFF, USA) at 
1:5000 in blocking solution for 2 h at room temperature (RT).  
Following washing with PBST, filters were incubated with horse 
radish peroxidase (HRP)-conjugated anti-mouse IgG monoclonal 
antibody (BioRad, Hercules, CA, USA) diluted 1:3000 in blocking 
solution.  After additional washing in PBST washes, 
chemiluminescent detection was performed using the Super 
Signal® West Pico Chemiluminescent Substrate (Piercem 
Rockford, IL, USA).  Band quantification by densitometry with the 
Image Master® software (Amersham Biosciences) was performed 
as described (Farinha et al., 2004).   
 
4.4 METABOLIC LABELLING AND CFTR IMMUNOPRECIPITATION  
For pulse-chase assays, BHK cells stably expressing the 
various CFTR constructs were starved for 30 min in methionine-
free α–modified Eagles medium (MEM) (Invitrogen, USA).  Cells 
were then pulse-labelled for 30 min in the same medium 
supplemented with 150 µCi/ml [35S]-methionine (PerkinElmer, 
Boston, MA, USA).  Subsequently cells were then chased for 0, 
0.5, 1, 2 and 3 h in MEM medium supplemented with 5 % (v/v) FBS 
(Invitrogen, USA) and 1mM non-radioactive methionine (Sigma-
Aldrich, St-Louis, MO, USA) and then lysed in 1 ml of RIPA buffer 
(1 % (w/v) deoxycholic acid (Sigma-Aldrich); 1 % (v/v) Triton X-100 
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(Pharmacia Biotech, GE Healthcare, Chalfont St. Giles, UK); 0.1 % 
(w/v) SDS (Invitrogen, USA); 50 mM Tris, pH 7.4  and 150 mM 
NaCl (both from Sigma-Aldrich).  Following a 30 min centrifugation 
at 14000 g (4 °C), supernatant was immunoprecipitated (IP) using 
one of the above mentioned anti-CFTR antibodies and 25 µg 
protein G agarose beads (Roche, Basel, Switzerland), overnight 
(o/n) 4 °C with gentle rocking.  Beads were washed 3 times with 1 
ml RIPA buffer and protein was eluted by adding 60 µl of Laemmli 
sample buffer (see section 4.1, Chapter II) for 1 h at RT.  The 
samples were electrophoretically separated on a 7% (w/v) 
polyacrylamide gel.  Gels were pre-fixed with methanol/acetic acid 
(30:10:60) for 30 min, washed in water for 1 h and then, for 
fluorography, soaked in 1 M salicylic acid for one additional hour.  
After drying for 2 h at 80 °C under vacuum, gels were exposed to 
X-ray films (Fuji Super RX, Tokyo, Japan).   
Pulse-chase data for CFTR variants in Chapter III were 
performed by Marisa Sousa at the National Institute of Health Dr. 
Ricado Jorge (Lisbon, Portugal) 
 
4.4.1 DENSITOMETRY 
Fluorograms of gels were digitalised on a JX-330 scanner 
(Sharp Corporation, Japan).  Integrated peak areas were 
determined using the ImageMaster® software (Amersham 
Bioscience).   
 
4.4.2 STATISTICAL ANALYSIS 
 Quantitative results are shown as means ± SEM of n 
observations.  Comparisons between slopes of lines representing 
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degradation rates (regression lines) were made using a Student t 
test (Farinha et al., 2002).  The slope is known to follow a t 
distribution on a regression modelling procedure (Glantz, 1997; 
Helliwell and Jackson, 1994; Kleinbaum et al., 1988).  Therefore, 
slopes of two straight lines can be compared using a t distribution 
with n1 + n2 - 4 degrees of freedom where n1 and n2 are the number 
of points used on the regression procedures in groups 1 and 2, 
respectively.  To test for differences between groups of data at 
matching times of chase, an analysis of variance (ANOVA) was 
used.  To compare only tow sets of data, we used Student’s t test 
were differences are significant for p values < 0.05.   
 
5. CFTR FUNCTIONAL ANALYSIS 
5.1 IODIDE EFFLUX 
CFTR-mediated iodide efflux was measured at RT as 
described (Lansdell et al., 1998b) using the cAMP agonist forskolin 
(10 µM) and the CFTR potentiator genistein (50 µM; Sigma-
Aldrich). Prior to commencing experiments, BHK cells expressing 
CFTR variants were seeded onto 60-mm Petri dishes and 
incubated for 1h in loading buffer containing: 136 mM NaI, 3 mM 
KNO3, 2 mM Ca(NO3)2, 20 mM Hepes and 11 mM glucose (all from 
Sigma-Aldrich), pH 7.4 with 1 M NaOH; and then washed 
thoroughly with efflux buffer (136 mM NaNO3 replacing 136 mM 
NaI in the loading buffer). The amount of iodide in each sample of 
efflux buffer was determined using an iodide-selective electrode 
(MP225, Thermo Electron Corporation, Waltham, MA, USA).  
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5.2 PATCH-CLAMP ANALYSIS 
All single-channel data were generated by Zhe Xu, MSc, at 
Dr. David N. Sheppard’s laboratory at the University of Bristol, UK.   
CFTR Cl- currents were recorded in excised inside-out 
membrane patches using an Axopatch 200B patch-clamp amplifier 
(MDS Analytical Technologies) and pCLAMP data acquisition and 
analysis software (versions 6.0.4 and 9.2, MDS Analytical 
Technologies) as described previously (Lansdell et al., 1998b). The 
pipette (extracellular) solution contained (mM): 140 N-methyl-D-
glucamine (NMDG), 140 aspartic acid, 5 CaCl2, 2 MgSO4 and 10 N-
tris[Hydroxymethyl]methyl-2-aminoethanesulfonic acid (TES), pH 
7.3 with Tris ([Cl-], 10 mM). The bath (intracellular) solution 
contained (mM): 140 NMDG, 3 MgCl2, 1 CsEGTA and 10 TES, pH 
7.3 with HCl, ([Cl-], 147 mM; [Ca2+]free, <10-8 M) and was maintained 
at 37 °C. After their excision, membrane patches were voltage-
clamped at –50 mV and CFTR Cl- channels activated by the 
addition of ATP (1 mM; Sigma-Aldrich) and the catalytic subunit of 
protein kinase A (PKA; 75 nM; Promega UK) to the intracellular 
solution within 5 min of patch excision. In this study, we used 
membrane patches containing small numbers of active channels (≤ 
5). We determined the number of channels in a membrane patch 
from the maximum number of simultaneous channel openings 
observed during the course of an experiment. To minimize errors 
when counting the number of active channels, we employed the 
strategies described by (Cai et al., 2006). We recorded, filtered and 
digitized data, as described (Lansdell et al., 1998a). To measure 
single-channel current amplitude (i), Gaussian distributions were fit 
to current amplitude histograms. For Po analyses, lists of open and 
closed times were created using a half-amplitude crossing criterion 
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for event detection. Transitions < 1 ms in duration were excluded 
from the analyses and Po was calculated as previously described 
(Cai et al., 2006). 
 
6. IMMUNOCYTOCHEMISTRY 
Immunocytochemistry in Chapter III was performed as 
described previously (Mendes et al., 2005). In brief, BHK cells 
expressing CFTR variants were rinsed twice with cold phosphate 
buffer saline (PBS) and fixed with ice-cold 4 % (w/v) PFA (p-
Formaldehyde, Fluka BioChemica) in PBS for 20 min. After four 
washes with cold PBS at RT, non-specific staining was prevented 
by blocking with 1 % (w/v) bovine serum albumin (BSA) in PBS for 
30min.  Following blocking, cells were stained with Texas Red-
couple WheatGerm Agglutinin for 1 h and then permeabilized with 
Triton 0.02 % (v/v) for 20 min. Cells were then washed three times 
with PBS (10 min each at RT) and incubated with monoclonal anti-
CFTR antibody 570 (CFF, USA) and for 1 h with Alexa 488 
conjugated anti-mouse IgG. 
Cells were then washed three times with PBS (10min each 
at RT) and slides were mounted with Vectashield (Vector 
Laboratories, Burlingame, CA, USA) containing 4', 6-diamidino-2-
phenylindole dihydrochloride (DAPI; Sigma-Aldrich) to stain nuclei 
and covered with a glass coverslip. Immunofluorescence staining 
was observed and recorded on a confocal microscope Leica TCS 
SPE (Leica, Jehna, Germany) and respective software. No 
background staining or autofluorescence were observed with 
untransfected BHK cells (data not shown).  
Immunocytochemistry in Chapter IV was performed on 
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cover slips.  In brief, BHK cells expressing the different CFTR 
variants were plated on sterile cover slips and cultured in 35-mm 
tissue culture dishes for 1-2 days before use. Once fixed with 4 % 
PFA (p-Formaldehyde, Fluka BioChemica) for 20 min cells were 
then rinsed twice with phosphate buffer saline (PBS) containing 
MgCl2 and CaCl2. After four washes with PBS (MgCl2 and CaCl2) at 
RT, non-specific staining was prevented by blocking with bovine 
serum albumin (BSA; 1 % w/v) for 30 min. Cells were then washed 
three times with PBS (MgCl2 and CaCl2) (5 min each at RT) and 
incubated with monoclonal anti-CFTR antibody 570 and with Alexa 
532 anti-mouse for 1h. Cells were washed again three times with 
PBS (MgCl2 and CaCl2) (5 min each at RT) and slides were 
mounted with Vectashield (Vector Laboratories, Burlingame, CA, 
USA) containing 4',6-diamidino-2-phenylindole dihydrochloride 
(DAPI; Sigma-Aldrich) to stain nuclei and placed onto glass slides. 
Immunofluorescence staining was observed and recorded on a 
confocal microscope Leica TCS SPE (Leica, Jehna, Germany) and 
respective software. No background staining or autofluorescence 
were observed with untransfected BHK cells (data not shown). 
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III – FOLDING AND RESCUE OF A CFTR TRAFFICKING MUTANT 
REVEALED BY HUMAN-MURINE PROTEIN CHIMERAS 
1.  SUMMARY 
Impairment of the cystic fibrosis transmembrane 
conductance regulator (CFTR) Cl- channel causes cystic fibrosis 
(CF), a fatal genetic disease.  Here, we exploit interspecies 
differences between CFTR homologues using human (h) - murine 
(m) CFTR chimeras containing murine nucleotide-binding domains 
(NBDs) or regulatory domain (RD) on an hCFTR backbone to gain 
insight into CFTR structure and function.  Among 15 hmCFTR 
chimeras, all but 2 were correctly processed: one containing part of 
mNBD1 and another part of mNBD2.  Based on physico-chemical 
distance analysis of divergent residues between human and murine 
CFTR in the two misprocessed hmCFTR chimeras, we generated 
point mutations for analysis of CFTR processing and function.  We 
identified one amino acid substitution (K584E-CFTR) that disrupts 
CFTR processing in NBD1.  No single mutation was identified in 
NBD2 that disrupts protein processing.  However, a number of 
NBD2 mutants altered channel function.  Analysis of structural 
models of CFTR identified L581 as a residue interacting with K584 
in human CFTR.  Introduction of the E584-interacting murine 
residue (F581) in cis with K584E, rescued the processing and 
trafficking of K584E-CFTR.  We conclude that hmCFTR chimeras 
are a valuable tool to elucidate interactions between different 
domains of CFTR.  Our data also demonstrate that human-murine 
CFTR chimeras may be used to validate structural models of full 
length CFTR. 
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2.  INTRODUCTION 
Cystic fibrosis (CF) is the most common lethal genetic 
disease in the Caucasian population, resulting from the dysfunction 
of the cystic fibrosis transmembrane conductance regulator (CFTR) 
(Welsh et al., 2001). CFTR is a multi-domain protein containing 
1480 amino acid (aa) residues located at the apical membrane of 
epithelial cells where it functions as a chloride (Cl-) ion channel 
regulated by cAMP-dependent phosphorylation and cycles of ATP 
binding and hydrolysis (Gadsby et al., 2006; Sheppard and Welsh, 
1999). Based on its structure and function, CFTR (ABCC7) is a 
member of the ATP-binding cassette (ABC) transporter 
superfamily. It contains two membrane-spanning domains (MSDs), 
two nucleotide-binding domains (NBDs) and a unique regulatory 
domain (RD) with multiple consensus phosphorylation sites and 
many charged amino acids (Riordan et al., 1989; Sheppard and 
Welsh, 1999). The most common disease-causing mutation, 
occurring in ~90% CF patients worldwide on at least one CFTR 
allele, is deletion of phenylalanine 508 (F508del) located in NBD1. 
A critical aspect of CF research is to understand how the 
F508del mutation disrupts CFTR function at the molecular and 
cellular levels. Depending on the cell type examined, the 
maturation efficiency of wild-type (wt)-CFTR protein is 25%-70% 
(Lukacs et al., 1993; Varga et al., 2004; Ward and Kopito, 1994). 
By contrast, very little or virtually no functional F508del-CFTR 
reaches the cell surface because it is retained in the endoplasmic 
reticulum (ER) by the ER quality control (ERQC) machinery and 
targeted for degradation (Amaral, 2004). The exact nature of the 
structural divergence imposed on CFTR by absence of F508del, 
which is recognized by the ERQC (Lukacs et al., 1994; Qu and 
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Thomas, 1996) is currently unknown. To understand better how 
F508del perturbs CFTR structure, high-resolution structures of 
murine and human NBD1 as well as of human F508del-NBD1 
(Lewis et al., 2004; Lewis et al., 2005) have been resolved. 
However, the structure of human NBD1 incorporates a series of 
mutations, which rescue in vivo the cell-surface expression and 
function of F508del-CFTR (Pissarra et al., 2008). Thus, the 
available crystal structure of F508del-NBD1 plausibly corresponds 
to a partially corrected conformation of this domain. Based on 
these NBD1 structures and atomic-resolution structures of other 
ABC transporters (Hollenstein et al., 2007), molecular models of 
the CFTR protein have been developed (Mornon et al., 2008; 
Serohijos et al., 2008). These molecular models are a valuable 
guide for studies of CFTR structure and function. 
Another powerful approach to investigate the structure and 
function of human CFTR (hCFTR) is to examine interspecies 
differences to identify conserved and divergent regions. Since the 
identification and cloning of the human (hCFTR) gene (Riordan et 
al., 1989) various homologues have been isolated from different 
species (e.g. mouse, sheep, Xenopus, macaque, rabbit, bovine, 
killifish, salmon) all possessing a similar domain organisation to 
hCFTR (Chen et al., 2001). Nevertheless, significant interspecies 
differences in CFTR processing and function have been reported 
previously. For example, human and murine CFTR Cl- channels 
exhibit different patterns of channel gating (Lansdell et al., 1998a; 
Lansdell et al., 1998b), which are specified, in part, by amino acid 
sequence differences in the NBDs (Scott-Ward et al., 2007). 
Moreover, (Ostedgaard et al., 2007) identified differences in the 
processing of the F508del mutation between human, porcine and 
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murine CFTR. In this study, both porcine and murine F508del-
CFTR proteins were found to be at least partially processed like 
their wt counterparts and this processing was unaffected by the 
origin of the cell line where mutant proteins were expressed. Thus, 
cross-species CFTR chimeras appear an excellent resource to 
investigate the folding and functional consequences of interdomain 
interactions in CFTR. Indeed, insights into the biochemical 
properties of mCFTR subdomains in the context of hCFTR, as 
those provided by the present study, will help to further 
understanding of the structural and functional effects of the 
disease-causing mutations in both NBDs and validate existing 
structural models (Mornon et al., 2008; Rosenberg et al., 2004; 
Serohijos et al., 2008). 
In the present work, we aimed to identify the structural 
features of hCFTR (mis)folding, using a human-murine 
comparative approach, by investigating whether CFTR domains 
(NBDs and RD) are structurally interchangeable between human 
and murine CFTR. Our data reveal that two chimeras (one in NBD1 
and another in NBD2) failed to be processed into their mature 
forms. Systematic mutagenesis of the divergent murine residues 
present in these chimeras followed by biochemical and functional 
studies revealed that K584E is responsible for the maturation 
defect of the hmNBD1-chimera. Furthermore, replacement of L581 
(interacting with K584 in the structure of hNBD1) by the 
corresponding murine aa (F581) rescued the maturation of K584E-
CFTR. Thus, our results demonstrate that hmCFTR chimeras can 
be used to identify critical residues responsible for both structural 
and functional differences between human and murine CFTR. 
Furthermore, the CFTR mutants generated here constitute a 
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valuable resource to characterize the possible binding sites and 
mechanism of action of small molecules used in CFTR-assist 
therapies (Amaral, 2010). 
 
3.  RESULTS 
Human-murine recombinant CFTR cDNA 
A recombination strategy was used to generate hmCFTR 
chimeras (Scott-Ward et al., 2007). Because of the high degree of 
homology between human (h) and murine (m) CFTR sequences, 
homologous recombination frequently occurred within the murine 
domains rather than at the chimeric junction defined by the PCR 
primers. From the library of chimeras generated by (Scott-Ward et 
al., 2007), we focused on the following constructs in the present 
work (Figure III.1A): 562c-NBD1 (limits of inserted murine CFTR 
sequence, L433-V586); 12b-NBD1 (K518-V586); 323c-NBD2 
(M1260-S1419); 114c-NBD2 (M1260-R1412); 64a-RD (S654-
L834); and NBD1+2 (K518-V586; M1260-S1419). The latter NBD1 
+ 2 refers to chimera 12b + 323c, which is not the same as 
previously described in Scott-Ward et al., 2007, hence we term it 
hereafter, 12b-NBD1+323c-NBD2. As controls, we also analyzed 
F508del- and wt-human CFTR as well as murine CFTR. 
 
Processing efficiency of human-murine CFTR chimeras.   
The traffic of CFTR protein to the cell membrane can be 
assessed indirectly by its maturation. Indeed, wt-CFTR synthesized 
in the endoplasmic reticulum (ER) as a core-glycosylated, 
immature form, undergoes additional glycosylations through the 
Golgi apparatus to generate its mature form (band C; ~160-kDa) 
(Cheng et al., 1990; Lukacs et al., 1994). By contrast, due to its ER 
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retention, F508del-CFTR can only be detected as the core-
glycosylated, ER-specific immature form of CFTR (band B; ~150-
kDa) (Cheng et al., 1990). Quantification of these immature and 
mature forms at steady-state provides a measure of the extent of 
maturation of a given CFTR variant and also, indirectly, of its in 
vivo folding by ERQC protein conformation criteria. These data can 
also be interpreted as indicative of structural divergence between 
mutant and wt-CFTR. 
 When we evaluated the maturation efficiency of the 
hmCFTR chimeras by assessing their production of immature and 
mature CFTR protein at steady-state by Western blot analysis 
(WB) in the same cell line, we found that two chimeras failed to 
generate the mature form of CFTR (band C): clone 12b-NBD1 
(Figure III.1B; lane 9) and clone 114c-NBD2 (Figure III.1B; lane 7). 
Indeed, both these chimeras were only detected as their immature 
core-glycosylated ER-specific forms (150-kDa; band B) (Cheng et 
al., 1990). These results contrast with all the other chimeras 
analysed: 12b-NBD1+323c-NBD2 (Figure III.1B; lane 2), 323c-
NBD2 (lane 3); 562c-NBD1 (lane 4); 64a-RD (lane 5); human (lane 
1) and murine CFTR (lane 8). For each of these CFTR constructs, 
the mature form was detected, albeit at varying levels (Figure 
III.1B). After quantification of independent experiments (n = 10), the 
rank order of processing efficiency was: 323c-NBD2 (129 ± 6%) >> 
murine (86 ± 5%) = human (83 ± 3%) = 562c-NBD1 (80 ± 4%) = 
64a-RD (77 ± 4%) > 12b-NBD1+323c-NBD2 (67 ± 5%). 
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Figure III.1 – Biochemical analyses of hmCFTR chimeras. (A) Schematic 
representations of the hmCFTR chimeras. The light grey segments represent 
mCFTR inserts (numbers designate length in mCFTR amino acid residues) 
into hCFTR (dark grey rectangles). Note that the extent of protein sequence 
classified here as mCFTR is depicted as the largest contiguous protein 
sequence inserted into each construct that is flanked at each end by hCFTR 
residues (i.e. residues that differ between mCFTR and hCFTR sequences). 
Therefore, sequences of residues which are common to both mCFTR and 
hCFTR and may extend beyond the mCFTR blocks are denoted here as 
hCFTR because they do not represent deviations from the human CFTR 
sequence. The continuous lines and co-ordinates indicate the chimeric 
junctions defined by the PCR primers and confirmed here by sequencing, 
while the dashed lines and co-ordinates show the original C-termini of NBD1 
and NBD2 (Riordan et al., 1989). For further information, see the Results. (B) 
Western blot analysis of hmCFTR chimeras transiently expressed in HEK-293 
cells using the anti-CFTR antibody 596 (CFF, USA). The amount of total 
protein applied was 60 µg. The positions of bands B and C are indicated by 
arrows. Data shown are representative of multiple experiments (n = 10). 
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Additional chimeric constructs analysed by WB in 
transiently transfected HEK-293 cells included: 20b-NBD1 (T531-
Y647); 966c-NBD1 (I481-V546); 158a-NBD2 (M1220-D1409); 
189b-NBD2 (M1220-Y1381); 207c-NBD2 (V1226-N1420); 51a-RD 
(F653-M837); 52a-RD (T654-V693); 71a-RD (T654-L834); 85a-RD 
(T654-V837). Each of these hmCFTR chimeras was normally 
processed (data not shown). 
 
When we compared the murine aa sequences of the two 
non-processed chimeric proteins (12b-NBD1 and 114c-NBD2) with 
their corresponding human regions, we found that 12 and 27 aa 
residues diverge between the human and murine sequences of 
12b-NBD1 and 114c-NBD2, respectively (Figure III.2). To identify 
which of these residues accounts for the failure of these chimeric 
proteins to mature, we selected those residues with greatest 
sequence divergence between human and murine CFTR based on 
physico-chemical distance (PCD) (Grantham, 1974). Thus, we 
identified 6 residues in 12b-NBD1 and 12 residues in 114c-NBD2 
(Table III. I). 
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Figure III.2 – Alignment of murine NBD1 and NBD2 amino acid sequences in 
the hmCFTR chimeras 12b-NBD1 and 114c-NBD2 with the corresponding 
sequences of hCFTR. (A) For clone 12b-NBD1 (aa 518-586) there are 12 
residues divergent between the amino acid sequences of human and murine 
CFTR. The alterations with highest PCD values (indicated by black filled 
circles) were selected for site-directed mutagenesis to introduce these amino 
acid substitutions into the hCFTR cDNA. The 6 CFTR constructs generated 
were: E527Q, E528Q, S531T, K536Q, I539T and K584E. (B) For clone 114c-
NBD2 (aa 1260-1412) there are 27 residues divergent between the amino 
acid sequences of human and murine CFTR. The alterations with highest 
PCD values (indicated by black filled circles) were selected for site-directed 
mutagenesis to introduce these amino acid substitutions into the hCFTR 
cDNA. The 12 CFTR constructs generated were: T1263I, P1290T, K1302Q, 
Y1307N, Q1309D, S1311K, R1325K, V1338T, C1344Y, L1367I, D1394G and 
E1409D. Numbers refer to amino acid co-ordinates in human CFTR. The 
alignment of the murine region of 114c-NBD2 was extended until residue 
1419 to highlight differences between it and the hmCFTR chimera 323c-NBD2 
(M1260-S1419) (see Discussion). The known (NBD1) and predicted (NBD2) 
secondary structures of the NBDs are shown above the sequence alignments 
with α-helices labeled as "H" and ß-sheets labeled as "S"; orange denote the 
F1-type ATP-binding core subdomain; blue the ABC α-subdomain and green 
the ABC ß-subdomain (Lewis et al., 2004). For clarity, H6b and H6c are 
labeled 6b and 6c. Boxes denote the positions of the ABC signature and 
Walker B motifs. 
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Table III. I – List of physico-chemical distance (PCD) of all CFTR variants produced by site-directed mutagenesis and results showing 
proportion of processed CFTR protein at steady state (% band C vs total CFTR expressed) and iodide efflux function corresponding to 
peak intensity (%) and delay in peak response (min). Among all CFTR mutants described in this study we found 4 that are already 
listed in the CFTR mutation database. E527Q, T1263I, P1290T and I539T. Mutation E527Q was found in a patient thought to be mildly 
affected with CF, with age of onset at 20 years with chronic bronchietasis and malabsorption. The second mutation T1263I was 
followed because of asthma, and sweat chloride were in the borderline range (30-60 mmol/L). Whereas, mutation P1290T, was found 
in the asymptomatic husband, from Northeast Italy, of a CF carrier. Finally, I539T is described as a revertant mutation. % band C and 
% of peak intensity are means ± SEM (n = 5) and (n = 6) respectively. 
 
       Iodide Efflux Function 
Mutations 
Mutation  
Database 
Physico-
Chemical 
Distance (PCD) 
% Band C 
±SEM  (n = 5) 
% Peak intensity 
±SEM (n = 6) 
Peak response  
delay (min) 
WT-CFTR - - 81% ± 3%  100% ± 8% - 
F508del-CFTR - - - 6% ± 1% - 
E527Q Mild CF 29 64% ± 5%  46% ± 4% 1 min 
E528Q - 29 86% ± 5% 135% ± 16% 0 
S531T - 58 87% ± 6% 71 ± 5% 1 min 
K536Q - 53 69% ± 3% 51% ± 4% 0 
I539T Revertant mutation 89 112% ± 5% 49% ± 6% 1 min 
L581F - - 118% ± 3% 48% ± 3% 1 min 
L581F-K584E - - 125% ± 2% 67% ± 14% 0 
K584E - 56 - 0.06% ± 0.5% 0 
T1263I Mild CF 89 75% ± 3% 31% ± 8% 1 min 
P1290T Asymptomatic 38 87% ± 3% 92% ± 10% 0 
CFTR Chimeras 
 73 
       Iodide Efflux Function 
Mutations 
Mutation  
Database 
Physico-
Chemical 
Distance (PCD) 
% Band C 
±SEM  (n = 5) 
% Peak intensity 
±SEM (n = 6) 
Peak response  
delay (min) 
K1302Q - 53 72% ± 3% 37% ± 2% 1 min 
Y1307N - 143 82% ± 2% 70% ± 5% 0 
Q1309D - 61 79% ± 4% 26% ± 2% 1 min 
S1311K - 121 73% ± 4% 33% ± 7% 1 min 
R1325K - 26 64% ± 6% 47% ± 2% 1 min 
V1338T - 69 88% ± 2% 37% ± 11% 1 min 
C1344Y - 194 71% ± 4% 86% ± 4% 0 
L1367I - 5 72% ± 5% 36% ± 5% 1 min 
D1394G - 94 78% ± 4% 93% ± 12% 1 min 
E1409D - 45 70% ± 3% 43% ± 5% 2 min 
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Processing of point mutants at residues divergent between 
human and murine CFTR in NBD1 and NBD2.  The above 6 NBD1 
and 12 NBD2 point mutants were introduced into full-length CFTR, 
and the constructs used to generate stable BHK cell lines and 
CFTR protein expression assessed by WB analysis (Figure III.3). 
 
 
Figure III.3 – Biochemical analysis of CFTR variants in NBD1 and NBD2. 
Western blot analysis of total protein extracts from BHK cells stably 
expressing the indicated CFTR variants in NBD1 (A) and NBD2 (B) using the 
anti-CFTR antibody 596 (CFF, USA). The amounts of total protein applied 
were: 20 µg for wt and F508del and 40 µg for all other CFTR variants. The 
positions of bands B and C are indicated by arrows. Quantification of these 
data is provided in Table III.I. Data shown are representative of multiple 
experiments (n = 18). 
 
With one exception (K584E), all point mutants derived from 
12b-NBD1 (Figure III.3A) were processed (lanes 3-7) similarly to 
wt-hCFTR (lane 1). Like F508del (Figure III.3A, lane 2), K584E 
(lane 8) only generated immature CFTR protein (band B; 150-kDa). 
By contrast, all point mutants derived from 114c-NBD2 were 
processed to the fully-glycosylated (band C; 160-kDa) form (Figure 
III.3B; lanes 1-6 and 9-14) like wt-hCFTR (lane 7). These data 
suggest that all CFTR constructs except K584E are delivered to the 
cell surface. Results from quantification of the mature form (as 
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percentage of total expressed) for each of the CFTR point mutants 
studied (Table III.I) show that PCD is not inversely correlated with 
extent of protein processing. 
 
Functional characterization of point mutants at residues 
divergent between human and murine CFTR in NBD1 and 
NBD2.   
To investigate the function of the above 6 NBD1 and 12 NBD2 
point mutants, we used the iodide efflux technique, which is a 
convenient method to assay the function of a large population of 
CFTR Cl- channels in intact cells. When cells expressing wt-CFTR 
are treated with 10 µM forskolin (Fsk), a cAMP agonist, and 50 µM 
genistein (Gen), a CFTR potentiator, a robust efflux of I- is obtained 
(Figure III.4). 
 
 
 
Figure III.4 – Continues on next page. 
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Figure III.4 – 
Time courses of 
iodide efflux from 
BHK cells stably 
expressing CFTR 
variants in NBD1 
and NBD2. (A) 
wt- (open 
squares long 
dashed line), 
F508del-CFTR 
(open circles 
dotted line) and 
murine-CFTR 
(open triangles 
medium dashed 
line); (B) E527Q 
(black circles), 
E528Q (black 
squares), S531T 
(black triangles); 
(C) K536Q (black 
inverted 
triangles), I539T 
(black diamonds) 
and K584E (black 
hexagons); (D) 
T1263I (open 
circles), P1290T 
(open squares), 
K1302Q (open 
triangles), 
Y1307N (open 
inverted 
triangles); (E) Q1309D (open diamonds), S1311K (open hexagons), R1325K 
(gray circles), V1338T (gray squares); (F) C1344Y (gray triangles), L1367I 
(gray inverted triangles), D1394G (gray diamonds) and E1409D (gray 
hexagons). During the periods indicated by the black bars, cells were 
stimulated with the cAMP agonist forskolin (10 µM) and the CFTR potentiator 
genistein (50 µM).  (G) Functional analysis of CFTR variants in NBD1 and 
NBD2. Data are the magnitude of CFTR-mediated iodide efflux elicited by the 
indicated CFTR constructs expressed in BHK cells and cultured at 37 ºC. For 
each construct, the peak value of iodide efflux stimulated by forskolin (10 mM) 
and genistein (50 mM) in the time-courses shown in A-F are expressed as a 
percentage of that of wt-CFTR. For comparison, the magnitude of CFTR-
mediated iodide efflux elicited by F508del-CFTR and wild-type murine CFTR 
are shown.  Data are means ± SEM (n = 6); where not shown error bars are 
smaller than symbol size.  Asterisks indicate values that are significantly 
different from wt-CFTR (p < 0.05). 
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Like cells expressing F508del-CFTR (Figure III.4A, G), 
those expressing K584E-CFTR failed to elicit an efflux of I- when 
treated with forskolin and genistein (Figure III.4C, G). The likely 
explanation for this result is the lack of K584E-CFTR expression at 
the cell membrane, as suggested by the absence of mature CFTR 
protein (Figure III.3A). All other NBD1 and NBD2 mutants that 
generated mature CFTR protein (Figure III.3) elicited an efflux of I- 
albeit with varying intensity compared with that of wt-CFTR (Figure 
III.4A, G). For most NBD1 and NBD2 mutants, the magnitude of I- 
efflux was less than that of wt-CFTR; for two mutants in NBD2 
(P1290T- and D1394D-CFTR), it was the same; and for one NBD1 
mutant (E528Q-CFTR), the magnitude of I- efflux was greater than 
that of wt-CFTR (Figure III.4B and Table III.I). 
Taken together, and consistent with the biochemical data 
(Figure III.3 and Table III.I), our iodide efflux data suggest that most 
of the NBD1 and NBD2 mutants exhibited channel activity, arguing 
that they reach the cell surface. These data also show that PCD is 
also not inversely correlated with extent of CFTR activity (Table 
III.I). By contrast, the agonists had barely any effect on cells 
expressing K584E-CFTR (Figure III.4C,G) a result which is 
consistent with the trafficking defect of this mutant (Figure III.3A). 
 
Characterization of the processing defect of K584E-CFTR.   
The lack of maturation and of detectable activity for the 
K584E-CFTR mutant, led us to investigate the surrounding 
environment of K584 in the published structure of hNBD1 (Lewis et 
al., 2005). The rationale behind this approach was to uncover 
which residues near to or interacting with K584 (hNBD1) might 
contribute to the putative conformational change caused by the 
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K584E mutation. We found that K584E-hNBD1 interacts with L581 
(Figure III.5) and that in K584E, the glutamic acid residue at 
position 584 becomes solvent exposed (data not shown). In 
mNBD1, E584 interacts with F581 preventing exposure of this 
acidic residue (data not shown). 
 
Figure III.5 – Stereo 
ribbon diagram of 
human F508del-
NBD1 structure (PDB 
entry 2BBT) revealing 
the positions of L581 
and K584. The 
trafficking mutant 
K584 identified in this 
study is shown in red 
and its interacting 
residue L581 in 
orange. Also shown: 
the LSGGQ motif 
(light blue); the 
Walker B (purple) and 
the RE (pink); and RI 
(yellow). The I539 
residue (site of the 
F508del-revertant 
when mutated into T) 
is depicted in black and the Q637 residue (site of the F508del-NBD1 
solubilizing mutation Q637R) in dark blue. 
 
 
Thus, we postulated that replacing L581 by a phenylalanine 
residue (as in mNBD1) might improve CFTR folding and rescue the 
processing defect of K584E-CFTR. To test this hypothesis, we 
introduced L581F in cis with K584E-CFTR by site-directed 
mutagenesis (L581F-K584E-CFTR) and generated the 
corresponding stable cell line as well as one expressing L581F-
CFTR. We then analyzed these cell lines in parallel with that 
expressing K584E-CFTR by biochemical (Figure III.6A, E-G), cell 
biology (Figure III.7) and functional approaches (Figures III.6B-D, 
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and 8). 
Figure III.6A demonstrates that both L581F (lane 2) and 
L581F-K584E (lane 3) were detected as their fully-glycosylated 
forms (band C), in contrast to K584E-CFTR (lane 1), for which only 
immature protein could be detected. We interpret these data to 
suggest that K584E is rescued by L581F possibly mediated by the 
side chain of phenylalanine 581 that fills the empty space left by 
the removal of K584 (Figure III.5), as occurs in the structure of 
mNBD1 (Lewis et al., 2004). 
 
Figure III.6A – Rescue of 
the trafficking defect of 
K584E-CFTR by L581F-
CFTR. (A) Biochemical 
analysis by Western blot 
of total protein extract 
from BHK cells stably 
expressing: K584E (lane 
1), L581F (lane 2), L581F-
K584E (lane 3), wt (lane 
4) and F508del (lane 5). 
The positions of bands B 
and C are indicated by arrows. Quantification of these data is provided in 
Table III.I. Data shown are representative of multiple experiments (n = 6). 
 
The magnitude of I- efflux elicited by L581F-CFTR (Figure 
III.6B-D) was smaller than that of wt-CFTR. However, that of 
L581F-K584E-CFTR was intermediate between L581F and wt-
CFTR (Figure III.6D). Furthermore, when cells expressing K584E-
CFTR were incubated at 26 °C for 24 h (Figure III.6C,D) they 
generated an efflux of I- similar to that of F508del-CFTR expressing 
cells incubated at 26 °C for 24 h, albeit this response of K584E-
CFTR was 5-fold smaller than that of wt-CFTR at 37 °C. These 
data suggest that like F508del-CFTR (Denning et al., 1992), the 
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processing of K584E-CFTR is temperature-sensitive. At 26 ºC, 
some K584E-CFTR protein is delivered to the cell membrane 
because the trafficking defect of this mutant is (at least partially) 
reverted at this permissive temperature. 
 
 
Figure III.6B-C-D – Restoration of CFTR-mediated iodide efflux to K584E by 
the revertant mutation L581F. (B) Time courses of CFTR-mediated iodide 
efflux from BHK cells stably expressing wt- (long dashed line), F508del- (open 
circles), K584E- (black circles), L581F (black triangles) and L581F-K584E 
(black inverted triangles) cultured at 37 ºC and (C) wt- (long dashed line), 
F508del- (black squares) and K584E- (open diamonds) cultured at 26 ºC. 
During the periods indicated by the black bar, forskolin (10 µM) and genistein 
(50 µM) were added to the efflux buffer to stimulate CFTR-mediated iodide 
efflux. (D) Magnitude of peak iodide efflux elicited by the indicated CFTR 
constructs expressed in BHK cells and cultured at either 37 or 26 ºC. For each 
construct, the peak value of iodide efflux stimulated by forskolin (10 mM) and 
genistein (50 mM) in the time-courses shown in B and C are expressed as a 
percentage of that of wt-CFTR. Data are means ± SEM (n = 6); where not 
shown, error bars are smaller than symbol size; asterisks indicate values that 
are significantly different from wt-CFTR (p < 0.05), incubated at 37 ºC. 
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To learn more about the stability of the K584E-, L581F- and 
L581F-K584E-CFTR variants, we examined the turnover rate of 
their immature forms (band B) and their efficiency of conversion 
into their mature forms (band C). Pulse-chase analyses, followed 
by CFTR immunoprecipitation (Figure III.6E) demonstrate that the 
turnover rates of band B of both L581F- (Figure III.6F, open 
squares) and L581F-K584E-CFTR (Figure III.6F, filled triangles) 
were the same as those of wt-CFTR (Figure III.6F, filled circles).  
However, the turnover rate of K584E-CFTR (Figure III.6F, filled 
diamonds) was significantly (p<0.05) reduced compared to those of 
L581F-, L581F-K584E-, wt- and F508del-CFTR (Figure III.6F, open 
circles). Consistent with the data in Figure III.6F, the processing 
efficiencies of L581F- (Figure III.6G, open squares) and L581F-
K584E-CFTR (Figure III.6G, filled triangles) were not significantly 
different from those of wt-CFTR (Figure III.6F, filled circles). Taken 
together, these data suggest that the immature form of K584E–
CFTR is significantly stabilized compared to those of L581F-, 
L581F-K584E-, wt- and even of F508del-CFTR. 
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Figure III.6E-F-G – Rescue of the trafficking defect of K584E-CFTR by 
L581F-CFTR. (E) Turnover and processing of wt-, F508del-, K584E-, L581F- 
and L581F-K584E-CFTR determined in BHK cells stably expressing these 
CFTR variants by pulse-chase experiments followed by immunoprecipitation 
(IP). Cells were radiolabelled with [35S]methionine for 20 min and then chased 
for the indicated times (0, 0.5, 1, 2, 3 h) before lysis with RIPA-buffer and IP 
with the anti-CFTR antibody M3A7 (Chemicon, USA) (see Methods). After 
electrophoresis and fluorography, images were analysed by densitometry. 
The positions of bands B and C are indicated by arrows. (F) Rate of turnover 
of the immature form of CFTR (band B) shown as the natural logarithm of the 
amount of band B at a given time of the chase (A) relative to the amount at 
the beginning of the experiment (Ao). (G) Efficiency of conversion into mature 
CFTR (band C) shown as the percentage of band C detected at a given time 
of the chase (A) relative to the amount at the beginning of the experiment (Ao). 
In F and G, data are mean ± SEM (n = 4). Asterisks indicate values that are 
significantly different from those of wild-type CFTR (p < 0.05). In  F and G, the 
lines are the fit of first-order regressions to the data. [Data obtained by Marisa 
Sousa at the Department of Genetics, National Institute of Health (INSA), 
Lisbon, Portugal; with permission]. 
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Localization of K584E-, L581F- and L581F-K584E-CFTR by 
immunofluorescence.   
Our biochemical studies demonstrated that K584E–CFTR is 
only detected in its immature form, suggesting that it is misfolded 
and retained in the ER. To test this possibility and learn whether 
the biochemically detected rescue of K584E-CFTR by L581F-
CFTR (mature form), indeed corresponds to protein present at the 
cell surface, we used immunofluorescence and confocal 
microscopy. 
Immunodetection of CFTR showed that the K584E-CFTR 
mutant (Figure III.7C1) was predominately located intracellular like 
F508del-CFTR (Figure III.7B1), albeit with K584E-CFTR exhibiting 
a more perinuclear distribution. By contrast, L581F- (Figure 
III.7D1), L581F-K584E- (Figure III.7E1) and wt-CFTR (Figure 
III.7A1) were mostly found at the plasma membrane co-localizing 
with wheat germ agglutinin (WGA) (Figure III.7, A3, D3 and E3). 
When applied without permeabilization, WGA is a marker of the cell 
surface that recognizes sialic acid and N-acetylglucosaminyl 
sugars highly prevalent at the plasma membrane (Glozman et al., 
2009). We interpret these data to suggest that L581F- rescues the 
cell surface expression of K584E, confirming our biochemical and 
functional data, which argue that L581F-CFTR is a revertant 
mutant for K584E-CFTR. 
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Figure III.7 – Immunolocalization of CFTR constructs in BHK cells. BHK cells 
expressing the indicated CFTR variants grown at 37 ºC were analyzed by 
immunofluorescence using the anti-CFTR antibody 570 (upper panels) and 
the anti-wheat germ agglutinin (WGA) coupled with Texas Red (middle 
panels). The lower panels show the merged images with nuclei stained blue 
with DAPI. Data shown are representative of n = 4 experiments. Bar = 25 µm. 
 
 
Single-channel behaviour of the processing mutant K584E-
CFTR.   
In previous research, we demonstrated that revertant (e.g. 
G550E-CFTR; (Roxo-Rosa et al., 2006)) and solubilising mutations 
(e.g. F429S-F494N-Q637R; (Pissarra et al., 2008)) rescue defects 
in CFTR channel gating in addition to promoting the cell surface 
expression of F508del-CFTR. We therefore speculated that L581F-
CFTR might augment the single-channel activity of K584E-CFTR. 
To test this possibility, we used the excised inside-out configuration 
of the patch-clamp technique. 
Figure III.8A demonstrates that addition of ATP (1 mM) and 
PKA (75 nM) to the intracellular solution bathing excised inside-out 
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membrane patches from cells expressing K584E-, L581F- and 
K584E-L581F-CFTR cultured at 37 ºC activated single-channels 
with properties and regulation characteristic of wild-type CFTR. By 
contrast, culture of cells expressing F508del-CFTR at reduced 
temperature is required to observe channel activity and these Cl- 
channels possess properties distinct from those of wild-type CFTR 
((Denning et al., 1992; Roxo-Rosa et al., 2006); Figure III.8A). To 
quantify single-channel activity, we measured single-channel 
current amplitude (i) and open probability (Po). Consistent with the 
behaviour of other CFTR variants containing point mutations in the 
NBDs (Sheppard and Welsh, 1999), K584E-, L581F- and K584E-
L581F-CFTR had values of i similar to that of wild-type CFTR 
(Figure III.8B). 
The pattern of channel gating of wild-type CFTR is 
characterised by bursts of channel openings interrupted by brief 
flickery closures and separated by longer closures between bursts 
(Figure III.8A). The F508del mutation perturbs the rate of channel 
opening with the result that the closed time interval separating 
channel openings is increased greatly and Po attenuated markedly 
((Dalemans et al., 1991); Figure III.8A and C). Visual inspection of 
single-channel records suggested that the gating behaviour of the 
CFTR variants K584E-, L581F- and K584E-L581F-CFTR all 
resembled that of wild-type CFTR (Figure III.8A). Consistent with 
this idea, the Po of L581F-K584E-CFTR was the same as that of 
wild-type CFTR, while those of K584E- and L581F-CFTR were 
slightly reduced (Figure III.8C). Thus, K584E-CFTR profoundly 
disrupts CFTR processing, but only modestly affects the Cl- 
channel function of CFTR. Of note, these effects of K584E-CFTR 
are rescued by the revertant mutation L581F-CFTR 
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Figure III.8 – Single-channel analysis of the CFTR constructs K584E, L581F 
and K584E-L581F-CFTR. (A) Representative recordings of CFTR Cl- 
channels in excised inside-out membrane patches from BHK cells expressing 
the indicated CFTR variants cultured at 37 ºC. ATP (1 mM) and PKA (75 nM) 
were continuously present in the intracellular solution, voltage was -50 mV 
and there was a large Cl- concentration gradient across the membrane patch 
([Cl-]int = 147 mM; [Cl-]ext = 10 mM). Dotted lines indicate where channels are 
closed and downward deflections correspond to channel openings. For wt-, 
F508del-, K584E- and K584E-L581F-CFTR, membrane patches contained a 
single active channel, but for L581F-CFTR, the membrane patch contained 
two active channels. (B, C) Single-channel current amplitude (i) and open 
probability (Po) of the indicated CFTR variants recorded using the conditions 
described in A. Data are means + SEM (n = 4 – 5, except F508del-CFTR, 
where n = 10); asterisks indicate values that are significantly different from 
those of wild-type CFTR (p < 0.05). In C, Po values for F508del-CFTR are 
from (Roxo-Rosa et al., 2006).  [Electrophysiology data obtained by Zhe Xu, 
at Doctor David N. Sheppard’s laboratory at the Department of Physiology 
and Pharmacology, University of Bristol, UK; included with permission]. 
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4.  DISCUSSION 
In this study used human-murine CFTR chimeras and point 
mutants to explore the structural basis of differences in the function 
of human and murine CFTR (Lansdell et al., 1998a; Lansdell et al., 
1998b). 
 
Maturation of chimeras.   
With two exceptions, our data demonstrate that 
replacement of different protein regions in the NBDs and RD of 
hCFTR with the equivalent regions of mCFTR were without effect 
on CFTR processing. These data indicate that interchanging 
sections of human domains with the equivalent murine regions had 
no apparent consequence on the folding of the CFTR protein. 
However, two CFTR chimeras failed to mature: 12b-NBD1 and 
114c-NBD2, containing part of NBD1 (K518-V586) and NBD2 
(M1260-R1412), respectively. The hmCFTR chimera 12b-NBD1 
contains a conserved region of mNBD1 that includes the LSGGQ 
and Walker B motifs, while the hmCFTR chimera 114c-NBD2 
includes the LSHGH and Walker B motifs of mNBD2. Since these 
two regions of CFTR are very much conserved between human 
and murine CFTR, differences in aa residues can highlight how 
processing is abolished in these two mutants. Of note the 
processing of the NBD1+NBD2 chimera (12b-NBD1+323c-NBD2) 
was less efficient (67 ± 5%) than either human or mCFTR. This 
result implies that the two murine NBDs acquire better folding when 
they are together in the murine vs the human background and 
emphasizes the relevance of interdomain associations for folding of 
full-length CFTR. 
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It is interesting that the hmCFTR chimera 12b-NBD1 failed 
to be processed, because the hmCFTR chimera 966c-NBD1 
containing a wider portion of NBD1 (I481-V546) was correctly 
processed (data not shown). Thus, it would seem likely that the 
region present in 12b-NBD1 and absent in 966c-NBD1 (T547-
V586) contains the residue(s) causing the maturation defect of 12b-
NBD1. Indeed, the point mutant which we found to cause a failure 
in CFTR maturation (K584E-CFTR) lies exactly in this region. 
Remarkably, the 12b-NBD1+323c-NBD2 chimera (K518-V586; 
M1260-S1419), which contains the same murine portion of NBD1 
as 12b-NBD1, was found to be correctly processed. This result 
suggests that the presence of this murine NBD2 region (M1260-
S1419) is able to mask the structural cue of 12b-NBD1 which is 
recognized by the ERQC leading to its maturation defect. 
The hmCFTR chimera 114c-NBD2 also failed to be 
processed. Remarkably, another NBD2 chimera 323c-NBD2 
(M1260-S1419), with the same N-terminal boundary and just 7 
additional residues at its C-terminus (1413-1419) was found to be 
fully processed. By comparing this 7-aa extension of 323c-NBD2 
which is absent in 114c-NBD2, only one residue (at position 1419) 
was found to diverge between murine (S1419) and human (N1419) 
CFTR. It thus becomes apparent that this residue alone should 
rescue the trafficking defect of the 114c-NBD2 chimera. 
Interestingly, 323c-NBD2 was the hmCFTR chimera, which 
demonstrated higher processing efficiency than either human or 
murine CFTR. 
As for the RD hmCFTR chimeras analysed (data for 64a-
RD shown here and for 52a-RD, 71a-RD, 85a-RD not shown) we 
did not find any affects on CFTR processing. Consistent with these 
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results, transfer of the RD of mCFTR to hCFTR was without effect 
on CFTR channel gating (Scott-Ward et al., 2007). Taken together, 
these data likely reflect the high degree of structural plasticity of the 
RD. 
Our present and previous (Scott-Ward et al., 2007) data 
suggest that the structural requirements for protein processing and 
channel function are distinct. Previously, we demonstrated that the 
hmCFTR chimeras 562c-NBD1 (L433-V586) and 323c-NBD2 
(M1260-S1419) exhibited patterns of channel gating with only 
subtle differences from those of wt-hCFTR (Scott-Ward et al., 
2007). Only by simultaneous transfer of the mCFTR sequences 
L433-V586 and M1260-S1419 to hCFTR did the latter Cl- channel 
acquire the dramatically prolonged openings of the sub-
conductance state of murine CFTR (Scott-Ward et al., 2007). 
These data argue that optimal channel gating requires precise 
interactions between NBD1 and NBD2, a fundamental tenet of the 
ATP-driven NBD dimerisation model of CFTR channel gating 
(Vergani et al., 2005). However, our previous data (Scott-Ward et 
al., 2007) also raise the interesting possibility that channel gating, 
albeit sub-optimal, is possible when NBDs from two CFTR 
homologues are mixed. Nevertheless, and in contrast to optimal 
channel gating, which only occurs for most the favourable 
conformations, an increase in protein processing levels can also 
derive from improved trafficking efficiency, not necessarily related 
to improved folding. This is the case when ER retention motifs 
masked such as by removal of the arginine-framed tripeptides 
(AFTs), as we showed before for 4RK-F508del-CFTR (Roxo-Rosa 
et al., 2006). 
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Processing and activity of point mutants in NBD1 and NBD2.  
Biochemical studies of CFTR variants identified by physico-
chemical distance analysis of residues in 12b-NBD1 revealed that 
the mutation K584E disrupts the maturation of CFTR protein. By 
contrast, a similar analysis of 114c-NBD2 failed to identify CFTR 
variants that disrupt CFTR processing – mutation of the 12 
residues with highest physico-chemical distance between human 
and murine CFTR was without effect on CFTR maturation. This 
suggests that one or more of the remaining 15 sequence variations 
between human and murine CFTR in 114c-NBD2 accounts for the 
defective processing of this CFTR chimera. This argues that more 
conservative sequence changes might account for the failure of 
114c-NBD2 to process. Nevertheless, as discussed above, 
N1419S alone likely rescues the processing defect of 114c-NBD2. 
This argues that the interacting residues of N1419S cause the 
trafficking defect of the hmCFTR chimera 114c-NBD2. 
Our data also suggest that mutations in NBD1 have a more 
severe effect on CFTR processing than those in NBD2. Previous 
work supports this idea that NDB2 might play a less important role 
in the folding of full-length of CFTR. For example, CFTR constructs 
lacking NBD2 exit the ER (Cui et al., 2007) while deletion of NBD1 
prevented CFTR trafficking to the cell surface, whereas deletion of 
NBD2 did not impair CFTR processing (Pollet et al., 2000; Rich et 
al., 1993). Furthermore, CF-associated mutations are more 
prevalent in NBD1 than NBD2 
(http://www.genet.sickkids.on.ca/cftr/app).  Consistent with this 
idea, (Gregory et al., 1991) showed that the increased susceptibility 
of NBD1 mutations to misprocessing might be a result of the 
surrounding domains or the greater susceptibility of NBD1 mutants 
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to detection by the ERQC. 
Among the 20 point mutants described in this study (the 
above 18 point mutants plus L581F and L581F-K584E) we found 4 
that are listed in the CFTR mutation database 
(http://www.genet.sickkids.on.ca/cftr/app), namely: E527Q, T1263I 
and P1290T, which are described in association with mild CF, and 
I539T which is described as a F508del-revertant mutation (Table 
III.I). Our own data suggest that P1290T (associated with 
asymptomatic CF) is worthy of further study, since it almost does 
not affect CFTR processing nor function. This raises the interesting 
possibility that P1290T might be a sequence variation 
(polymorphism) like V562I (Choi et al., 2001b; Garcia et al., 2009; 
Roxo-Rosa et al., 2006). 
Regarding the CFTR channel activity (as determined by the 
iodide efflux technique) of these point mutants, there were some 
which although correctly processed exhibited significantly reduced 
activity. The most striking differences for the NBD1 mutants (Table 
III.I) were (% processing / % activity): E527Q (64/46); I539T 
(112/49); L518F (118/72), while for the NBD2 mutants, they were: 
T1263I (75/31); K1302Q (72/37); Q1309K (79/26); S1311K (73/33); 
V1338T (88/37); L1367I (72/36); E1409D (70/43). Curiously, the 
point mutant with the highest discrepancy was I539T, which 
rescues the trafficking defect of F508del-CFTR (DeCarvalho et al., 
2002). These data suggest that this revertant mutation greatly 
improves trafficking, but slows channel gating, which can be 
interpreted as evidence for some structural divergence from the 
native conformation of the wt channel. By contrast, the revertant 
mutation G550E, which enhances both CFTR trafficking and 
gating, was proposed to correct the defective folding of F508del-
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CFTR (Roxo-Rosa et al., 2006). 
Interestingly, by quantifying the maturation or function of 
these point mutants (Table III.I), we found no inverse correlation 
between PCD values and extent of processing or levels of CFTR 
activity. This argues that the context of the amino acid change 
overrides its nature. These data also emphasize the difficulty of 
making predictions about the functional consequences of missense 
mutations (and even more of patient phenotypes based on 
genotypes), thus demonstrating the necessity of experimental 
analyses. 
 
Characterization of K584E and Rescuing by L581.   
Like F508del-CFTR (Denning et al., 1992), the trafficking 
defect of K584E-CFTR is temperature sensitive. However, in 
contrast to F508del-CFTR, activity of K584E-CFTR Cl- channels 
was detected in cells cultured at 37 ºC, although this mutant could 
not be biochemically detected at the cell surface. Possible 
explanations for this apparent incongruence are (i) the higher level 
of channel activity exhibited by K584E-CFTR compared to that of 
F508del-CFTR and (ii) the possibility that K584E-CFTR might be 
stable at the cell surface, whereas F508del-CFTR is not (Hegedus 
et al., 2006). It should nevertheless be noted that although K584E-
CFTR exhibits some Cl- transport, its trafficking to the cell surface 
remains highly inefficient. This result is reminiscent of A455E and 
P574H, two CF mutations associated with a milder clinical 
phenotype (Sheppard et al., 1995). Even though production of the 
mature forms of A455E and P574H was reduced and very much 
delayed, A455E had channel activity similar to and P574H greater 
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than that of wild-type CFTR (Sheppard et al., 1995). Conversely, 
the NBD1 CF mutant G551D is processed correctly, but forms a Cl- 
channel with a profound gating defect that is not regulated by 
intracellular ATP (Bompadre et al., 2007; Cai et al., 2006). 
A further explanation for the discrepancy between the 
processing (biochemical) and functional data of K584E-CFTR, 
whereby this trafficking mutant might escape the ER via an non 
conventional route (Bannykh et al., 2000) also has to be discarded. 
Indeed, by immunofluorescence, we could not detect K584E-CFTR 
at the plasma membrane. It thus seems likely that only very little 
(below biochemical / immunofluorescence detection levels) of the 
K584E-CFTR reaches the cell surface, but once correctly inserted 
this CFTR variant has a significant capacity to transport Cl-. 
To understand the structural basis by which K584E disrupts 
the processing and function of CFTR, we used a model of full-
length CFTR (R. Ford, personal communication). This trafficking 
mutant lies on the highly conserved region of NBD1 where E584 is 
solvent exposed and interacts with L581. Accordingly, we changed 
the interacting residue in human CFTR (L581) to the corresponding 
residue in murine CFTR (F581) and found that it rescued the 
trafficking defect of K584E. In the crystal structure of NBD1 (Lewis 
et al., 2004; Lewis et al., 2005), it is likely that K584E disrupts the 
interaction of K584 with neighbouring residues and, hence, the 
folding of NBD1. The introduction of the L581F mutation likely 
restores the processing defect of K584E possibly mediated by the 
side chain of F581 that fills the empty space left by the removal of 
K584. Moreover, confirmation that both L581F and L581F-K584E 
are present at the cell surface was provided by functional studies 
(both iodide efflux and patch-clamp). 
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A further dimension of the present work is to use hmCFTR 
chimeras and point mutants in the NBDs to elucidate the protein 
motifs responsible for the differential efficiencies with which some 
small molecules modulate human and murine CFTR Cl- channels. 
For example, Lansdell et al. (Lansdell et al., 1998a) demonstrated 
that the inorganic phosphate analogue pyrophosphate (PPi) 
potentiates robustly the gating behaviour of hCFTR, but is without 
effect on mCFTR. Using hmCFTR chimeras, we previously 
localized the binding site with which PPi interacts to enhance CFTR 
channel gating to NBD2 (Scott-Ward et al., 2007). Moreover, (de 
Jonge et al., 2009) tested a battery of CFTR correctors and 
potentiators for their effects on F508del-murine CFTR and 
demonstrated that all CFTR correctors tested rescued the cell-
surface expression of F508del-murine CFTR, whereas the majority 
of CFTR potentiators were without effect on F508del-mCFTR 
channel gating. These data argue that hmCFTR chimeras and 
point mutants in the NBDs are a valuable resource to elucidate the 
mode of action of CFTR potentiators. 
With this study of hmCFTR chimeras, we gained further 
insight into the structural and functional properties of CFTR 
domains. We identified an NBD1 trafficking mutant (K584E) which, 
despite being inefficiently processed, exhibits some activity as a 
regulated Cl- channel. Moreover, by using the available structure of 
NBD1, we predicted that substitution of another NBD1 residue 
(L581F) should restore the processing defect of K584E. 
Experimental confirmation of this prediction here has shown how 
the use of hmCFTR chimeras can not only elucidate interactions 
between different domains of CFTR, but also validate structural 
models of full-length CFTR. 
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IV	   –	   THE IMPACT OF THE REGULATORY EXTENSION (RE) AND 
REGULATORY INSERTION (RI) LOCATED IN THE FIRST NUCLEOTIDE 
DOMAIN ON THE IN VIVO PROCESSING OF FULL-LENGTH CFTR 
 
1.  SUMMARY  
Cystic fibrosis (CF) transmembrane conductance regulator 
(CFTR), product of the gene defective in CF, functions as a 
chloride (Cl-) channel at the apical membrane of epithelial cells. 
The primary CF-causing mutation F508del affects CFTR by both 
preventing it’s reaching the cell surface and impairing channel 
gating. Structural knowledge of CFTR is crucial in order to gain a 
better understanding of how disease-associated mutations 
compromise its maturation and activity. Crystal structures of wt- 
and F508del-NBD1 indicated that they do not substantially differ, 
except for two segments designated regulatory extension (RE, 
Ser654-Gly673) and regulatory insertion (RI, Ala412-Leu428). 
Here, we firstly assessed the impact of removing RE and RI 
(separately and jointly) on the in vivo processing of full-length wt- 
and F508del-CFTR. Secondly, we evaluated the effect of known 
F508del-revertant mutations (R1070W, G550E) on maturation of 
RE/RI variants. Results show that ∆RE, ∆RI and ∆RE/∆RI are 
efficiently processed on wt-, but not on F508del-CFTR, although 
∆RE/∆RI-wt-CFTR exhibits lower steady-state maturation levels. 
Functional characterization by iodide efflux shows that ΔRE- and 
ΔRI-wt respond to agonists, ΔRE causing a significant functional 
decrease, despite that ΔRE-wt is predominantly at the plasma 
membrane and ΔRI-wt mostly in the ER with faint membrane 
staining. Neither ΔRE- nor ΔRI-F508del exhibit detectable activity, 
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being both located in the ER. Finally, R1070W-ΔRI-F508del (but 
not R1070W-ΔRE-F508del) undergoes maturation. Altogether, 
these results help to elucidate the structural changes that account 
for the F508del defect and may be of use to elucidate the 
mechanism of action of correctors. 
 
 
2.  INTRODUCTION 
Cystic Fibrosis (CF) is a life-threatening autosomal 
recessive disorder mostly affecting the Caucasian population 
(Rowe et al., 2005). CF arises from mutations in the gene coding 
for the cystic fibrosis transmembrane conductance regulator 
(CFTR), a 1480 residue protein, member of the ATP-binding 
cassette (ABC) transporters superfamily. CFTR, however, unlike 
other ABC family members is not a transporter, instead it functions 
as a chloride channel at the apical membrane of epithelial cells 
(Gadsby et al., 2006; Welsh et al., 2001). One of the most critical 
clinical symptoms of CF is the accumulation of thick mucus in the 
airways, but other complications, such as pancreatic insufficiency 
and intestinal obstruction are also frequently observed. To date 
over 1,600 alterations have been described in the CFTR gene, 
most presumed to be pathologic 
(http://www.genet.sickkids.on.ca/cftr/app). However, one single 
mutation, F508del (a 3bp deletion causing absence of 
phenylalanine 508) accounts for ~70% of CF chromosomes 
worldwide and is present in ~90% of patients. The primary structure 
of CFTR reveals high homology to a large superfamily of proteins 
involved in active transport across cell membranes, the so called 
ABC transporters (ATP-binding cassette) (Hughes, 1994). CFTR 
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consists of two repeats each comprising a transmembrane domain 
(TM), followed by a cytosolic nucleotide-binding domain (NBD) 
(Riordan et al., 1989). A regulatory domain (RD), unique to CFTR, 
is located between the NBD1 and TM2. The TMs are linked to the 
NBDs via intracellular loops (ICLs). Nucleotide biding (NBD1) 
together with RD phosphorylation and hydrolysis (NBD2) are 
required to open and close the channel pore, respectively 
(Sheppard and Welsh, 1999). The transmembranar segments are 
linked by six extracellular and four cytoplasmic loops, and two 
glycosylation sites were described in the fourth extracellular loop.  
The biosynthesis and maturation of CFTR is a complex and 
inefficient process, even for the wt protein. The most critical 
problem associated with the F508del mutation, located in NBD1, is 
its impaired folding, which prevents this mutant protein to traffic 
properly to the cell membrane (Riordan, 2005) due to its retention 
in the endoplasmic reticulum (ER) by the ER quality control 
(ERQC) which targets it for degradation via the ubiquitin-
proteasomal pathway (UPP) (Vashist and Ng, 2004). The folding 
and maturation of this mutant protein can however be rescued by 
several treatments namely low temperature (26-28 ºC) incubation 
(Denning et al., 1992), certain compounds (chemical and 
pharmacological chaperones) or in the presence of genetic 
suppressors, i.e., second-site mutations reverting the trafficking 
defect associated with F508del-CFTR (Teem et al., 1993). The 
functional activity of F508del-CFTR can also be restored by some 
(but not all) of these manipulations indicating that the trafficking 
and gating defects associated with F508del-CFTR are uncoupled. 
Moreover, the F508del-CFTR defect is thus “rescuable” and that a 
therapeutic strategy to correct its misfolding to the benefit a vast 
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majority of CF patients appears as feasible (Thibodeau et al., 
2005).  
Comparison of the high-resolution structures of wt and 
mutant forms of the CFTR protein could lead to a direct 
understanding of the molecular basis of CF. Ultimately, different 
intra- and inter-molecular interactions between the two proteins are 
the main cause of CF. The lack of such 3D structures has been a 
major drawback in providing a structural basis to find therapeutic 
small molecules compensating for the basic defect and to 
understand at a molecular level how different mutations perturb the 
overall structure of the protein. Structural analogy models based on 
high-resolution structures of other ABC transporters compensate 
for this lack of knowledge (Mornon et al., 2008; Serohijos et al., 
2008). Moreover, the previously reported high-resolution structures 
of wt- and F508del-NBD1 have provided valuable information about 
the structure of this domain (Lewis et al., 2004; Lewis et al., 2005). 
Although the topologies of both structures are nearly identical the 
presence of F508del causes a change in the surface properties 
around the NBD1 mutation (Lewis et al., 2004; Lewis et al., 2005). 
Many of the crystallization studies to date have used murine CFTR 
NBD1 because of its increased solubility relative to the human 
protein (Lewis et al., 2004; Thibodeau et al., 2005). Moreover, we 
have also shown previously that solubilizing mutants of human 
NBD1 used for crystallization lead to partial correction of F508del 
(Pissarra et al., 2008), making it difficult to elucidate the real 
structural differences between human wt- and F508del-NBD1. 
Nevertheless, two NBD1 segments may be responsible for 
the altered surface properties of F508del-NBD1, namely the 
regulatory extension (RE) and regulatory insertion (RI), so-called 
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given their absence from NBDs of other ABC family members. The 
RI is a ~30-residue insert between the first two ß-strands of the 
NBD1 ß-subdomain and is composed of two short α-helices 
separated by a disordered linker (see Figure IV.2 showing the 
stereo ribbon diagram of human F508del-NBD1, PDB entry 2BBT) 
where some of the structural features reported for RI and RE are 
highlighted. The RE is at the C-terminus of NBD1, where it extends 
~20 residues longer than canonical ABC domains forming a helix 
packing against NBD1 at the NBD1-NBD2 interface. It was 
suggested that both RE and RI are positioned to impede formation 
of the NBD1–NBD2 dimer anticipated to occur during channel 
gating and both these regions were suggested to be 
conformationally dynamic (Lewis et al., 2004; Lewis et al., 2005) 
namely upon phosphorylation (PKA sites serines 660/670 and 
serine 422, respectively) (Dahan et al., 2001). Recent NMR data 
indeed showed significant conformational flexibility of the C-
terminus of NBD1 (RE) (Kanelis et al., 2009). There is nevertheless 
some controversy regarding the boundaries of these regions. One 
study proposed the RI between residues 412-428 and the RE being 
flanked by residues 655-670 (Lewis et al., 2004; Lewis et al., 
2005). Another study proposed that residues 404-435 determined 
the RI and residues 639-670 the RE (Csanady et al., 2005). Yet in 
another study, the RE was defined between residues 554-573 
(Kanelis et al., 2009). 
Here, we hypothesized that the dynamic flexibility of these 
regions may also result in exposure of hydrophobic surfaces thus 
contributing to the dynamic instability of NBD1 and the low folding 
efficiency of both wt- and F508del-CFTR. Our first goal was to 
assess the structural/functional impact of removing the RE and the 
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RI (separately or jointly) on the in vivo processing of full-length 
CFTR. Secondly, we aimed to evaluate the effect on these variants 
of in cis mutations previously described to correct the defect of 
F508del-CFTR folding, namely: R1070W (4th intracellular loop, 
ICL4) (Serohijos et al., 2008) and G550E (NBD1, ABC "signature" 
motif) (Roxo-Rosa et al., 2006). To this end, we produced ∆RE and 
∆RI variants of wt- and F508del-CFTR, alone, together (∆RE/∆RI) 
and with those 2 point mutations by in vitro mutagenesis and used 
them to generate BHK stable cell lines. 
Our data reveal that all wt-CFTR variants, namely ∆RE, ∆RI 
and ∆RE/∆RI are efficiently processed, although ∆RE/∆RI exhibits 
lower steady-state levels of maturation. Their functional 
characterization by iodide efflux shows that removal of the RE 
causes a significant decrease in the function of wt-CFTR, despite 
that immunofluorescence data show that ΔRE-wt is predominantly 
at the plasma membrane, whereas ΔRI-wt shows mostly ER 
localization with only faint membrane staining. ΔRE- and ΔRI-
F508del are located in the ER. Results also show that R1070W-
ΔRI-F508del (but not R1070W-ΔRE-F508del) undergoes 
maturation, suggesting that RE may synergize with the fourth ICL4 
to stabilize the F508del-CFTR structure. 
 
 
3.  RESULTS 
The Regulatory Extension and Regulatory Insertion 
Given the discrepancies in defining the borders of the RI and RE 
(Csanady et al., 2005; Kanelis et al., 2009; Lewis et al., 2004), we 
performed a sequence alignment of wt- human and mouse NBD1 
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with NBD domains from other ABC transporters to determine what 
regions would be defined has the RE and RI (Figure IV.1) 
 
 
Figure IV.1 – Sequence alignment of human and mouse NBD1 with NBD 
domains from other ABC transporters. Numbering of the secondary structure 
elements for CFTR NBD1 is indicated in shaded blocks in the top row were ß-
strands are in light bleu and α-helices are in orange (Lewis et al., 2005). 
Protein Data Bank ID codes are indicated in parentheses. Residues in dark 
bleu indicate high sequence conservation in ABC domains. Solid circles 
indicates where phosphorylation by PKA was observed in the mNBD1 
structure (Lewis et al., 2005). (A) The regulatory insertion (RI) and (B) 
regulatory extension (RE) are highlighted in gray blocks. 
 
 
In the present work, we have defined the RE as serine 654 
to glycine 673 (Figure IV.1A and IV.2), unlike previous studies 
(Csanady et al., 2005; Lewis et al., 2004; Lewis et al., 2005) but 
similarly to (Kanelis et al., 2009). The RI is defined here by alanine 
412 to leucine 428 (Figure IV.1B and IV.2), consistently with Lewis 
et al. (Lewis et al., 2004). 
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Figure IV.2 – Stereo ribbon diagram of human F508del-NBD1 structure (PDB 
entry 2BBT). The LSGGQ motif is shown in light blue, the Walker B in pink 
and the RE and RI in red and orange, respectively. 
 
 
Processing efficiency of ΔRE and ΔRI constructs 
Our first goal was to study the structural impact of removing 
the RE and the RI on full-length CFTR by ERQC criteria, through 
assessment of its in vivo processing. The polypeptidic chain of 
CFTR undergoes different post-translational modifications as its 
glycidic residues go through the secretory pathway to produce the 
fully-glycosylated mature form of the protein (Lukacs et al., 1994). 
We can monitor the glycosylation state of CFTR by WB thus giving 
us the possibility of distinguishing the wt protein form the 
processing mutant (F508del). Wt-CFTR is characterized by the ER 
core-glycosylated form of the protein, known as band B (150 KDa) 
and the fully-glycosylated mature form of CFTR, known as band C 
(170-180 KDa). In contrast, F508del-CFTR can only be detected as 
the core-glycosylated form of the protein due to its ER retention. 
Consequently, the glycosylation status of a protein can be used to 
RE and RI 
 105 
determine whether a given protein variant has passed the ERQC. 
When we evaluated the maturation efficiency of the various 
CFTR constructs lacking the RE and RI, assessed by the 
respective levels of immature and mature forms at steady-state, we 
found that wt-CFTR ∆RE (Figure IV.3A; lane 3), ∆RI (lane 5) and 
∆RE/∆RI (lane 7) are efficiently processed similarly to wt-CFTR 
(lane 1). These data suggest that these variants acquire a native 
(folded) conformation in vivo. Like F508del-CFTR (lane 2), these 
results contrast with the same constructs placed in a F508del-
CFTR background (Figure IV.3A; lane 4, 6 and 8) where they were 
only detected as the immature core-glycosylated ER-specific forms 
(150-kDa; band B). Quantification of these data (n = 3) indicate the 
following percentages of processing for these CFTR variants: ∆RE-
R1070W-wt (116 ± 7%) >> ∆RE-wt (91 ± 8%) >> ∆RI-wt (59 ± 2%) 
= ∆RE-G550E-wt (53 ± 8%) = ∆RI-G550E-wt (51 ± 4%) > ∆RI-
F1070W-F508del (19 ± 3%) > ∆RI-G550E-F508del (3 ± 1%) (Table 
IV.I, Figure IV.3B). 
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Figure IV.3 – Biochemical analyses of CFTR. (A) Western blot analysis using 
the anti-CFTR antibody 596 (CFF, USA) of total protein extracts from BHK 
cells stably expressing: wt (lane 1), F508del (lane 2), ΔRE-wt (lane 3), ΔRE-
F508del (lane 4), ΔRI-wt (lane 5), ΔRI-F508del (lane 6), ΔRE/ΔRI-wt (lane 7), 
ΔRE/ΔRI-F508del (lane 8), ΔRE-R1070W-wt (lane 9), ΔRE-R1070W-F508del 
(lane 10), ΔRI-R1070W-wt (lane 11), ΔRI-R1070W-F508del (lane 12), ΔRE-
G550E-wt (lane 13), ΔRE-G550E-F508del (lane 14) and ΔRI-G550E-wt (lane 
15). The amounts of total protein applied were: 30 µg for wt and F508del and 
40 µg for the other CFTR variants). The positions of bands B and C are 
indicated by arrows. Data shown are representative of multiple experiments 
(n=4). (B) Bar graph with quantification data of panel A (data from Table IV.I). 
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Table IV.I – Results showing proportion of fully processed CFTR protein (% 
band C) vs. total CFTR expressed. 
 
CFTR Mutants % band C 
Wt 100% 
ΔRE-wt 91 ± 8 % 
ΔRI-wt 59 ± 2 % 
ΔRE/RI-wt 37 ± 2 % 
ΔRE/R1070W-wt 116 ± 7 % 
ΔRI/R1070W-F508del 19 ± 3 % 
ΔRE/G550E-wt 51 ± 4 % 
ΔRE/G550E-F508del 3 ± 1 % 
ΔRI/G550E-wt 53 ± 8 % 
 
 
 
Our second goal was to evaluate the effect on the ΔRI and 
ΔRE variants of in cis mutations previously described or suggested 
to correct the folding defect of F508del-CFTR, namely: G550E 
(Roxo-Rosa et al., 2006) and R1070W (Mornon et al., 2008). By 
WB analysis, wt-CFTR variants lacking the RE and F508del-CFTR 
lacking RI in cis with R1070W (Figure IV.3A; lanes 9,12 
respectively) evidenced the presence of their fully-glycosylated 
forms. Conversely, the presence of R1070W in cis with F508del-
CFTR ∆RE (lane 10) and wt-CFTR ∆RI (lanes 10,11, respectively) 
only indentified their core-glycosylated forms. Additionally, wt- and 
F508del-CFTR variants lacking both the RE (lanes 13,14) and RI in 
cis with G550E (lane 15) showed the mature form of the protein 
known as band C. For all these CFTR constructs, the mature form 
was detected, albeit at varying levels. 
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Functional characterization of wt- and F508del-CFTR lacking 
the RE and RI 
To investigate the function of the wt- and F508del-CFTR 
∆RE and ∆RI, we used the iodide efflux technique, which is a 
convenient method to assay the function of a large population of 
CFTR Cl- channels in intact cells. When cells expressing wt-CFTR 
are treated with 10 µM forskolin (Fsk) a cAMP agonist and 50 µM 
genistein (Gen) a CFTR potentiator, a robust efflux of I- is obtained 
(Figure IV.4).  
 
Figure IV.4 – (A-B) Time course of Iodide efflux from BHK cells expressing: 
wt- (black circles), F508de-CFTR (black squares), ΔRE-wt (black triangles), 
ΔRI-wt (black inverted triangles), ΔRE-F508del (open triangles) and ΔRI-
F508del (open inverted triangles). During the periods indicated by the bar, 
forskolin (10 µm) and genistein (50 µm) were present in the efflux buffer. Data 
are means (n=6) at each time point. Where not shown, error bars are smaller 
than symbol size. (C) Magnitudes of peak iodide efflux generated by the same 
CFTR constructs expressed as a percentage of that of wt-CFTR. Asterisks 
indicate significant differences from wt-CFTR (p < 0.05). Data are expressed 
as means ± SEM (n = 6) at each point. 
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Like cells expressing F508del-CFTR (Figure IV.4A; black 
squares), cells expressing ∆RE- (Figure IV.4B; open triangles) and 
∆RI-F508del-CFTR (Figure IV.4A; open inverted triangles) failed to 
elicit an efflux of I- when treated with forskolin and genistein. The 
likely explanation for this result is the lack of ∆RE- and ∆RI- 
F508del-CFTR expression at the cell membrane, as suggested by 
the absence of mature CFTR protein (Figure IV.3). For ∆RE- 
(Figure IV.4A; black triangles) and ∆RI- wt-CFTR (Figure IV.4A; 
black inverted triangles) mutants elicited an efflux of I- albeit with 
varying intensity compared with that of wt-CFTR (Figure IV.4A; 
black circles). These results indicate that production of the mature 
form of the CFTR protein (Figure IV.3) results in the expression at 
the cell surface. Moreover, the magnitude of I- efflux for ∆RE-wt 
was significantly lower than that of wt-CFTR (diagonal stripes and 
solid black bars, respectively in Figure IV.4C). The magnitude of I- 
efflux for ∆RI-wt was the same as that of wt-CFTR (vertical stripes 
and solid black bars, respectively in Figure IV.4C) and those for 
∆RE-F508del and of ∆RI-F508del were the same as that of 
F508del-CFTR (diagonal- and vertical stripes-solid gray bars and 
solid black bars, respectively in Figure IV.4C). 
Taken together, our iodide efflux data suggests wt-CFTR 
variants lacking the RE and RI exhibit channel activity which is 
consistent with the biochemical data (Figure IV.3) arguing that they 
reach the cell surface. However, the agonist had barely any effect 
on cells lacking the RE and RI on a F508del-CFTR background a 
result which is consistent with the trafficking defect of both these 
mutants (Figure IV.3). 
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Turnover and processing of wt- and F508del-CFTR lacking the 
RE and RI  
To learn more about the stability of the ∆RE- and ∆RI- wt- 
and F508del-CFTR variants, we examined the turnover rate of their 
immature forms (band B) and their efficiency of conversion into 
their mature forms (band C). 
For F508del-CFTR, the absence of the RE and RI (dashed 
and dotted lines, respectively in Figure IV.5E) did not alter the 
turnover rate of band B (solid line, Figure IV.5E). Also, the 
efficiency of processing of ∆RE-wt and ∆RI-wt (dashed and dotted 
lines, respectively in Figure IV.5D) was slightly increased relatively 
to wt-CFTR (solid line, Figure IV.5D). Moreover, for wt-CFTR the 
turnover rate of ∆RE-wt and ∆RI-wt (dashed and dotted lines, 
respectively in Figure IV.5C) was significantly higher (p<0.05) 
compared to wt-CFTR (solid line, Figure IV.5C). These results 
could be due to decreased stability of the immature forms of ΔRE 
and ΔRI of wt-CFTR. However, since both these variants also 
generate higher levels of their respective mature forms (Figure 
IV.5D), the higher turnover rates of immature forms should be 
interpreted as increased maturation efficiency of ΔRE and ΔRI in 
comparison to wt-CFTR. 
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Figure IV.5 – Turnover and processing of wt-, F508del- alone or in cis with 
∆RE and ∆RI. (A–B) BHK cells expressing ∆RE-wt, ∆RI-wt and wt-CFTR (A); 
∆RE-F508del, ∆RI-F508del and F508del-CFTR (B) were radiolabelled with 
[35S]methionine for 20 min and then chased at indicated times (0, 0.5, 1, 2, 
3h). The positions of bands B and C are indicated by arrows. (C and E) 
Turnover of band B for wt- (C) and F508del-CFTR (E) in the absence and 
presence of ∆RE and ∆RI. Lines are the fit of first-order regressions to the 
data. Data are the natural logarithm of the amount of band B at a given time of 
chase (A) relative to its amount at the beginning of the experiment (Ao). (D) 
Efficiency of processing into band C for wt-CFTR in the absence and 
presence of ∆RE and ∆RI. Data are represented as the percentage of band C 
detected at a given time point during the experimental chase relative to Ao. 
Symbols and error bars are means SEM of n = 3 experiments. 
 
 
Localization of wt- and F508del-CFTR lacking the RE and RI by 
immunofluorescence 
Our biochemical studies demonstrated that ∆RE- and ∆RI- 
F508del-CFTR is only detected in its immature form, suggesting 
that it is misfolded and retained in the ER. Whereas, ∆RE and ∆RI 
wt-CFTR is detected as the mature form of protein indicating that it 
has passed the ER or undergone processing. To determine the 
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localization of all these CFTR variants we used 
immunofluorescence and confocal microscopy. 
Immunodetection of CFTR showed that the F508del-CFTR 
mutants lacking the RE and RI (Figure IV.6) was predominately 
located intracellular like F508del-CFTR (Figure IV.6). By contrast, 
∆RE- and ∆RI-wt-CFTR and wt-CFTR (Figure IV.6) were mostly 
found at the plasma membrane, albeit ∆RI-wt exhibiting some 
perinuclear distribution. We interpret these data to suggest that 
some of protein produced by the ∆RI-wt having a reduced 
processing efficiency (Table IV.I; 59 ± 2%) is possibly retained in 
the ER. 
 
Figure IV.6 – Immunolocalization of CFTR constructs in BHK cells. BHK cells 
expressing the indicated CFTR variants grown on cover slips at 37 ºC were 
analyzed by immunofluorescence using the anti-CFTR antibody 570 (CFF, 
USA). Nuclei staining were performed with DAPI. CFTR variants analysed are 
indicated above each column. Bar = 25 µm. 
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4.  DISCUSSION 
In this study we studied processing and function of CFTR 
variants lacking the RE and RI alone, together (RE/RI) or in cis with 
other known mutations (R1070W and G550E) so has to better 
understand the interfaces that have not yet been reported in the 
vicinity of the F508 residue. Of note, a recent biophysical study of 
CFTR NBD1 (Lewis et al., 2010) proposed that increased exposure 
of the F508 region and increased dynamics in its vicinity (509–511 
loop) could promote aberrant intermolecular interactions that 
prevent F508del-CFTR trafficking in vivo. 
 
Characterization of the ∆RE and ∆RI constructs 
Our biochemical data demonstrated that removing the 
regulatory extension (RE) and insertion (RI) but also both 
regulatory segments (∆RE/∆RI) were without major effect on the 
folding of wt-CFTR. However, the processing efficiency of these wt-
CFTR variants was greatly affected namely for ∆RI (59 ± 2%) and 
mostly for ∆RE/∆RI (37 ± 2%) in comparison both to ∆RE (91 ± 8%) 
and wt-CFTR itself (100%). Conversely, removing the RE causes a 
significant decrease in the function of wt-CFTR. These results 
suggest that the presence of the RI is critical for the efficiency of 
wt-CFTR folding, greatly improving trafficking, whereas presence of 
RE is necessary for efficient channel gating. The latter result is 
consistent with recent NMR data for a NBD1-RD construct showing 
that phosphorylation of the RD (which includes the RE) uncovers 
the NBD1 surfaces required for its dimerization with NBD2 and 
channel activation (Kanelis et al., 2009). 
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Data from immunofluorescence shown here also evidence 
localization of the ∆RE- and ∆RI-wt-CFTR mostly at the plasma 
membrane, which correlates with our biochemical and functional 
data. Of note, some perinuclear distribution found for ∆RI-wt also 
correlates well with the low processing efficiency of this CFTR 
variant. 
Additionally, biochemical and immunofluorescence studies 
of the same CFTR variants in a F508del-CFTR background 
revealed that they both fail to mature and traffic to the plasma 
membrane, reflecting that CFTR processing mutants also fail to 
traffic through the Golgi to the plasma membrane (Cheng et al., 
1990). Consistently, both variants also failed to elicit an efflux of I- 
when treated with forskolin and genistein. Plausibly, these F508del-
CFTR variants are recognized by the ER quality control due to 
some degree of failure in acquiring a native conformation. 
Our data showing increased maturation efficiency of ΔRE 
and ΔRI in comparison to wt-CFTR, leads to suggest that both the 
RE and the RI contribute indeed to destabilize full-length CFTR, as 
suggested by (Mornon et al., 2008). It is still thus somewhat 
surprising that removal of these regions did not cause rescuing of 
F508del-CFTR processing. 
 
Effect of revertants on processing of the ΔRE and ΔRI variants of 
F508del-CFTR 
DeCarvalho et al. (DeCarvalho et al., 2002) identified the 
revertant G550E and demonstrated that it partially rescues the 
processing defect and enhances Cl- currents in Fisher rat thyroid 
(FRT) epithelial of F508del-CFTR (DeCarvalho et al., 2002). 
Subsequently, we proposed that G550E rescues the trafficking and 
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gating defects of F508del-CFTR by correcting its folding (Roxo-
Rosa et al., 2006). Our biochemical data shown here for ∆RE-
G550E-F508el-CFTR demonstrating rescue of this variant concur 
with these data. 
Mutation of the arginine residue at codon 1070 has been 
associated with different disease consequences; R1070P and 
R1070Q with "severe" pancreatic insufficiency and R1070W with 
"mild" pancreatic sufficiency and/or CBAVD - congenital bilateral 
absence of the vas deferens (Krasnov et al., 2008). Additionally, 
Mornon et al. (Mornon et al., 2008) proposed that the presence of 
this basic residue in the ICL4 was a specific feature of CFTR when 
compared to other transporters and thus could represent a highly 
critical factor in CFTR MSD/ NBD interface. The same authors also 
speculate to the presence of a cavity in the NBD1/ ICL4 interface of 
the F508del protein could be filled by a small aromatic molecule 
thus allowing for a novel formation between NBD1 and ICL4 
consequently the correction of CFTR folding defect would be 
achieved (Mornon et al., 2008). Consistent with the NBD1/ ICL4 
interaction our previous biochemical data showed correction of 
F508del-CFTR folding defect by R1070W (data not shown).  
Additionally, biochemical data included here validate this idea, by 
demonstrating rescue of ∆RI-F508del when in cis with R1070W. 
Moreover, we interpret these results by the fact that the 
hydrophobic side chain of the tryptophan (W) allows for a new 
hydrogen bond formation between NBD1 and ICL4. Conversely, we 
were not able to see correction of the folding defect in F508del-
CFTR lacking the RE in cis with R1070W, suggesting that the RE, 
but not the RI, is required to stabilize the NBD1/ICL4 interaction. 
Consistently, structural evidence from Lewis et al. (Lewis et al., 
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2004) regarded the RE, located in helix H9b, as a more mobile 
structural element of NBD1 that would favor the folding of this 
domain.  
 
Structural Implications 
Lewis et al. (Lewis et al., 2004) showed minimal difference 
between the crystal structure of F508del and wt with the exception 
that orientation of the RE is 180º rotated between both structures. 
This suggests that the F508del mutation changes the surface 
environment of NBD1. Interestingly, one of the mutations used to 
promote domain solubilisation, Q637R, subsequently shown to be 
relevant to rescue in vivo the trafficking of F508del-CFTR (Pissarra 
et al., 2008), lies at the interface of the RE. Additionally, another 
mutation that partially corrects the processing of F508del (Pissarra 
et al., 2008), F429S lies at the end of the RI. Recent data by 
Kanelis et al. (Kanelis et al., 2009) support this idea, their 
observations suggesting a difference in conformation of the RI and 
RE in the two proteins (wt and F508del) that may include greater 
interactions of the RI and RE with the NBD1 core in F508del-NBD1 
in comparison to wt-NBD1. Additionally, through the use of surface 
plasmon resonance (SPR) previous data showed that deletion of 
Phe508 from NBD1 increased by 5-fold the affinity of the domain 
for Hsc70 vs wt-NBD1 (Scott-Ward and Amaral, 2009). These 
results show that F508del-NBD1 exposes its hydrophobic interior to 
the solution more often than wt-NBD1. Together with the data 
demonstrating rescue of F508del-CFTR by the NBD1 solubilizing 
mutations (Pissarra et al., 2008), they also show that there is an 
intradomain folding defect associated with F508del-NBD1, despite 
that interdomain associations may also be disrupted in F508del-
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CFTR. 
Furthermore, Atwell et al. (Atwell et al., 2010) proposed a 
NBD1 crystal structure that lacks the RI (∆405-436 and extending 
only to Gly646) but contains the entire canonical NBD fold (PDB 
code 2PZE). The data show that by removing the RI, truncated 
NBD1 has improved solubility and does not require the RE or any 
of the solubilizing mutations (Atwell et al., 2010). The same authors 
propose that the RI forms a crystal packing interaction with the Q-
loop of neighbouring molecules thus contributing to aggregation.  
This implies that some of the solubilizing mutations (F409L, F429S, 
F433L and F494N) located in the RI probably interfere with this 
interaction consequently improving solubilization.  Atwell et al. 
(Atwell et al., 2010) go on to propose that the RI, in models of 
CFTR, interacts with ICL1.  The study of Baker et al. (Baker et al., 
2007) also confirms the RI’s multiple interactions, by showing a 
more dynamic role for the RI which forms several transient 
interactions with NBD1. Along these lines, another explanation for 
the RI’s involvement in the reduction, stability, solubility and 
nucleotide binding of NBD1 might be that the RE may block some 
of the RI-binding sites.  Interestingly, our results demonstrating 
rescue of ∆RI-F508del when in cis with R1070W but not in ∆RE-
F508del are supportive of this idea. 
Taken together our results show the importance of the RI 
and RE play in overall structure of CFTR. Our data suggest that the 
RE contains residues that contact with the NBD1 core, probably 
thus favouring folding of this domain. On the other hand, the RI 
data suggests that this region plays a role in the intricate network of 
interactions plausibly leading to a tighter locking of the nucleotide 
at its non-conventional binding site (Mornon et al., 2008). 
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Future work regarding these regions will be required to gain 
a better understanding of the possible interaction of residue F508 
NBD1/ MSD2. Also, the current constructs, namely the ΔRI-
F508del-CFTR, will be extremely relevant to determine the 
mechanism of action of compounds of therapeutic potential aimed 
at correcting the folding defect of F508del-CFTR through a 
mutation-specific approach. By elucidating whether these 
compounds have synergistic effects with those of the known CFTR 
revertants and also by learning how they affect the ∆RE and ∆RI 
CFTR variants, we can learn whether they bind directly to CFTR 
and possibly their binding site can be inferred. 
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V – General Discussion 
Despite the enormous advances in CF research since the 
identification of the CFTR gene in 1989, further structural studies of 
full-length CFTR protein and of its isolated domains are necessary 
for a more comprehensive understanding of the major defect 
associated with F508del, the most prevalent mutation in CF 
patients. Indeed, F508del, located in the first nucleotide binding 
domain (NBD1) gives rise not only to a folding defect evidenced by 
the failure of a full-length protein to mature and reach the plasma 
membrane but also by its defective activity as a chloride channel 
(Cheng et al., 1990). However the "rescuability" of this trafficking 
mutant was first demonstrated by incubation at low temperature (26 
ºC) which resulted in maturation and membrane traffic of the 
F508del-CFTR protein (Denning et al., 1992). Since then, the 
therapeutic manipulation of the F508del-CFTR maturation as been 
the focus of intensive research efforts, which have described 
several chemical agents, genetic revertants and, more recently, 
also small molecules (correctors and/or potentiators) with the ability 
of correcting the trafficking and gating defects of this mutant (Van 
Goor et al., 2009; Van Goor et al., 2006). Nevertheless, 
understanding the major structural differences between F508del-
and wt-CFTR is still needed not only to clarify the mechanisms of 
action of those compounds but also to help design novel 
therapeutic molecules by "tailor-made" approaches (Amaral and 
Kunzelmann, 2007). 
During the course of this doctoral work, structural 
information about wt- and F508del-NBD1 (Lewis et al., 2004; Lewis 
et al., 2005) and the regulatory domain (RD) was put forward 
(Baker et al., 2007). There was also structural data for Sav1866 
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(Dawson and Locher, 2006), BtuCD-BtuF (Hvorup et al., 2007) and 
MsbA (Ward et al., 2007) all members of the bacterial ABC 
transporters. All of these have paved the way for new models of the 
CFTR protein generated based on molecular homology modelling 
methods (Mornon et al., 2008; Serohijos et al., 2008). 
Based on these models, on the atomic-resolution structures 
of CFTR NBD1 and on 2D low-resolution structures of full-length 
CFTR by cryo-EM (Awayn et al., 2005; Rosenberg et al., 2004; 
Zhang et al., 2009), the first goal of this doctoral work was to 
identify structural features of CFTR folding by using a cross-
species comparative approach between the human (h) and murine 
(m) CFTR orthologs. Human-murine CFTR chimeras were used 
previously to explore differences in CFTR channel gating between 
human and murine CFTR (Scott-Ward et al., 2007). Data from such 
studies revealed that transfer of both NBDs of mCFTR to hCFTR 
endowed the human CFTR Cl- channel with dramatically prolonged 
channel openings characteristic of mCFTR. 
In the present work, we used hmCFTR chimeras to 
investigate the role of the NBDs in CFTR processing and plasma 
membrane trafficking as a measure of their structural divergence 
by ERQC protein conformation criteria. With the exception of two 
hmCFTR chimeras, one located in NBD1 and the other in NBD2, all 
the chimeras tested generated mature CFTR protein. Based on 
physico-chemical distance analysis of divergent residues between 
human and murine CFTR in the two misprocessed hmCFTR 
chimeras, we generated point mutations for analysis of CFTR 
processing and function. We identified one amino acid substitution 
in NBD1 (K584E) that disrupts hCFTR processing. No single 
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mutation was identified in NBD2 that disrupts protein processing. 
However, a number of NBD2 mutants altered channel function. 
Previous work supports this idea that NDB2 might play a less 
important role in the folding of full-length of CFTR (Cui et al., 2007; 
Pollet et al., 2000). 
Analysis of structural models of CFTR identified L581 as a 
residue interacting with K584 in human CFTR. Introduction of the 
E584-interacting murine residue (F581) in cis with K584E, rescued 
the processing and trafficking of K584E-CFTR. We conclude that 
hmCFTR chimeras are a valuable tool to elucidate interactions 
between different domains of CFTR. Our data also demonstrate 
that human-murine CFTR chimeras may be used to validate 
structural models of full length CFTR. Finally, the CFTR mutants 
generated here constitute a valuable resource to characterize the 
possible binding sites and mechanism of action of small molecules 
used in "CFTR-assist" therapies. 
The various domain structures obtained to date have 
undeniably contributed to our understanding of the molecular basis 
of the CF pathology. Ultimately, detailed structural representation 
of proteins involved in disease can be used to direct design of 
drugs by "tailor-made" approaches. Studies performed in vivo 
designed to provide structural insight on full-length CFTR protein 
potentially allow a better understanding of dynamic interdomain 
rearrangements than the in vitro study of the isolated domains. 
In the second part of this doctoral work, we sought to 
understand the impact of two segments that differ from the wt- and 
F508del-NBD1 crystal structure designated regulatory extension 
(RE) and regulatory insertion (RI) which are absent in the NBDs of 
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other ABC transporters. 
Comparison of such crystal structures of wt- and F508del-
NBD1 indicates that the mutation does not affect the gross 
morphology of NBD1, but causes a change in the surface 
properties near to the NBD1 mutation (Lewis et al., 2004; Lewis et 
al., 2005). Differences between these structures also suggest that 
both wt and mutant NBD1 have two mobile regions. The first 
mobile region actually corresponds to the first 25 residues of the 
RD and was termed the regulatory extension (RE). The second 
mobile region is a 30-residue insertion, which, intriguingly, is 
absent in NBDs from other ABC transporters, called the regulatory 
insertion (RI). 
Recently, Zhang et al. (Zhang et al., 2009) described 2D 
low-resolution studies of purified full-length CFTR. When 
comparing their data with the 3D structure of Sav1866, they found 
that homology in the TM helices and most of the interconnecting 
loop are consistent between CFTR and Sav1866 (Zhang et al., 
2009). Interestingly, but perhaps not surprisingly, the main 
differences observed were in the RI and RE, besides in ~200 
amino acid of the RD and in additional residues at the N- and C-
termini.  
Since the high-resolution structures of wt- and F508del-
NBD1 were revealed it was believed that the F508del mutation did 
not affected the gross morphology of NBD1, but mostly the 
interdomain associations within CFTR. Subsequent studies have 
shown that F508del has a major negative impact on the NBD1 
surface interacting with MSD2, namely at the 4th intracellular loop. 
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However, more recent data, namely from our laboratory, 
indicate that the folding defect of F508del-CFTR must be already 
associated, at least in part, to F508del-NBD1. Firstly, mutations 
which help to solubilize isolated F508del-NBD1 in vitro also rescue 
the processing and membrane traffic defects of the full-length 
CFTR protein in vivo (Pissarra et al., 2008). Secondly, the affinity of 
F508del-NBD1 to the molecular chaperone Hsp70 (which 
recognizes hydrophobic motifs at the surface of polypeptidic 
chains) in vitro assessed by SPR (surface plasmon resonance) is 
5-fold higher than that of wt-NBD1 to the same chaperone, thus 
demonstrating that the mutant NBD1 is in a less native, more 
hydrophobic-exposed that that of the wt domain. It easily 
conceivable that disruption of NBD1 folding certainly will in turn 
perturb interdomain associations of full-length CFTR. 
Since the RI lies within the NBD1 whereas the RE is located 
a the C-terminus of NBD1 (considered by some already within RD), 
we hypothesized that the two NBD1 segments (RE and RI) may be 
responsible for the altered surface properties of F508del-NBD1. To 
test this assumption, we assessed the structural/functional impact 
of removing the RE and the RI (separately or jointly) on the in vivo 
processing of full-length wt- and F508del CFTR. Our biochemical 
data demonstrated that removing the regulatory extension (∆RE) 
and insertion (∆RI) but also both regulatory segments (∆RE/∆RI) 
were without major effect on the processing of wt-CFTR. 
Additionally, removing the RE, but not the RI, causes a significant 
decrease in the function of wt-CFTR. Similarly, removal of the RE 
or the RI from full length F508del-CFTR had no impact on its 
processing, failing to rescue its processing. Also our data showed 
increased maturation efficiency of ΔRE and ΔRI in comparison to 
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wt-CFTR, which suggest that the presence of both the RE and the 
RI contribute to stabilization of full-length CFTR. 
Furthermore, we also evaluated the effect of in cis 
mutations of G550E and R1070W on the ΔRI and ΔRE variants. 
G550E rescues the trafficking and gating defects of F508del-CFTR 
by correcting its folding (Roxo-Rosa et al., 2006) and R1070W 
located in the 4th intracellular loop was suggested to be able to 
rescue the trafficking defect of F508del-CFTR (Mornon et al., 
2008). Our biochemical data for ∆RE-G550E-F508del-CFTR, 
demonstrating rescue of this variant, support the data by Roxo-
Rosa et al. (Roxo-Rosa et al., 2006) and indicate that the RE does 
not interfere with the correction by G550E, which is located in the 
"ABC signature motif" (helix H5, α-subdomain) of NBD1. On the 
other hand, R1070W-ΔRI-F508del (but not R1070W-ΔRE-F508del) 
was shown here to undergo maturation. The R1070 residue, 
located in ICL4 might represent a highly critical factor in the CFTR 
MSD: NBD interface, as suggested by a recent computational 
study (Mornon et al., 2008). Indeed, another recent model of full-
length CFTR had proposed the presence of a cavity in the F508del-
NBD1/ICL4 interface of the full-length protein (Serohijos et al., 
2008). These authors also proposed that cavity could be filled by a 
small aromatic molecule thus allowing for a novel formation 
between NBD1 and ICL4 consequently the correction of CFTR 
folding defect would be achieved. Therefore, the fact that we 
observed correction of the folding defect of both F508del-CFTR 
and ∆RI-F508del-CFTR but not of ΔRE-F508del, by R1070W may 
imply the RE is required to stabilize the interaction between the 4th 
intracellular loop of the MSD2 and F508del-NBD1, but also that the 
RI is irrelevant for such interaction. These CFTR constructs 
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constitute an excellent model to test various compounds aimed at 
correcting the folding defect of F508del-CFTR, helping to define 
their binding site.  
 
Concluding remarks and perspectives for future work 
The studies presented in this dissertation had the overall 
aim of advancing the knowledge on the molecular/structural basis 
of CF. First, the use of human-murine CFTR chimeras was 
important to highlight crucial regions/residues playing a role in the 
conformational differences between human and murine CFTR 
protein. Also, such structural discrepancies between human and 
murine CFTR chimeras may in part account for the failure of some 
therapies indentified in CF mice to be efficacious in CF patients 
(and vice versa). Secondly, these results contributed not only to 
highlight relevant regions for the correct conformation of NBD1, but 
also for the validation of current structural models of full-length 
CFTR. Additionally, we investigated here two RE and RI segments 
located in NBD1 proposed to account for some of the structural 
differences observed between F508del and wt-NBD1. The RE (but 
not the RI) segment is likely to participate in the interdomain 
association of CFTR, occurring between the 4th intracellular loop of 
MSD2 and the surface of NBD1. 
An obvious follow-up of this work would be to test how 
compounds that correct the folding and function of F508del-CFTR 
affect the processing of the CFTR chimeras, point mutants, and RE 
and RI variants generated here, namely to observe whether they 
have additive (or synergistic effects) with those of variants reverting 
the F508del folding and trafficking defects. Also, by learning how 
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they affect these CFTR variants, can we plausibly learn whether 
and where they bind to CFTR. Ultimately, elucidating the 
mechanism of action of corrector compounds is essential for their 
pre-clinical validation as therapeutic agents for CF. 
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pNUT plasmid map showing its relevant elements: a MT 
(metallothionein) promoter to drive the expression of the cloned 
gene upstream of a SmaI site and a hGH (human growth hormone) 
poly A element downstream from the cloned gene.  The pUC 
backbone includes ampicillin resistance for bacterial selection and 
the mGHFR (mutant dihydrofolate reductase) gene, driven by the 
SV40 early promoter, confers methotrexate resistance for 
eukaryotic selection. 
 
 
 
 
